

**PRACTICE PARAMETER FOR THE ASSESSMENT AND TREATMENT OF
CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER**

ABSTRACT

This practice parameter describes the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) based on the current scientific evidence and clinical consensus of experts in the field. This parameter discusses the clinical evaluation for ADHD, comorbid conditions associated with ADHD, research on the etiology of the disorder, and psychopharmacological and psychosocial interventions for ADHD. **Key Words:** attention-deficit/hyperactivity disorder, children, adolescents, evaluation, treatment, practice parameter.

ATTRIBUTION

This parameter was developed by Steven Pliszka, M.D., principal author, and the AACAP Work Group on Quality Issues: William Bernet, M.D., Oscar Bukstein, M.D., and Heather J. Walter, M.D., Co-Chairs; Valerie Arnold, M.D., Joseph Beitchman, M.D., R. Scott Benson, M.D., Allan Chrisman, M.D., Tiffany Farchione, M.D., John Hamilton, M.D., Helene Keable, M.D., Joan Kinlan, M.D., Jon McClellan, M.D., David Rue, M.D., Ulrich Schoettle, M.D., Jon A. Shaw, M.D., and Saundra Stock, M.D. AACAP Staff: Kristin Kroeger Ptakowski and Jennifer Medicus.

The author wishes to acknowledge the following experts for their contributions to this parameter: Larry Greenhill, M.D., Timothy Wilens, M.D., Thomas Spencer, M.D., Joe Biederman, M.D., Mina Dulcan, M.D., Lily Hechtman, M.D., Paul Hammerness, M.D., John Hamilton, M.D., Caryn Carlson, Ph.D., Gregory Fabiano, M.A., William Pelham, Ph.D., James Swanson, Ph.D., and Daniel Waschbusch, Ph.D.

This parameter was reviewed at the Member Forum at the Annual Meeting of the AACAP in October, 2005.

From July, 2006 to September, 2006, this parameter was reviewed by a Consensus Group convened by the Work Group on Quality Issues. Consensus Group members and their constituent groups were as follows: Work Group on Quality Issues [Oscar Bukstein, M.D., Allan Chrisman, M.D., R. Scott Benson, M.D. and John Hamilton, M.D.]; Topic Experts [Larry Greenhill, M.D. and Russell Barkley, Ph.D.]; AACAP Work Group on Research [Larry Greenhill, M.D.]; AACAP Assembly of Regional Organizations [Joan Gerring, M.D. and Guy Palmes, M.D.]; and AACAP Council [Cynthia W. Santos, M.D. and Catherine Jaselskis, M.D.].

Disclosures of potential conflicts of interest for authors and Work Group chairs are provided at the end of the parameter. Disclosures of potential conflicts of interest for all other individuals named above are provided on the AACAP web site on the Practice Information page.

This practice parameter was approved by the AACAP Council on October 18, 2006.

This practice parameter is available on the Internet (www.aacap.org). Reprint requests to the AACAP Communications Department, 3615 Wisconsin Ave., NW, Washington, D.C. 20016.

© 2007 by the American Academy of Child and Adolescent Psychiatry.

INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD) (American Psychiatric Association, 2000) is one of the most common childhood psychiatric conditions. It has been the focus of a great deal of scientific and clinical study over the last century. Upon reviewing the voluminous literature on ADHD, the American Medical Association's Council on Scientific Affairs (Goldman et al., 1998) commented, "Overall, ADHD is one of the best-researched disorders in medicine, and the overall data on its validity are far more compelling than for many medical conditions." While scientists and clinicians debate the best way to diagnose and treat ADHD, there is no debate among competent and well-informed health care professionals that ADHD is a valid neurobiological condition that causes significant impairment in those whom it afflicts. These guidelines seek to lay out evidence-based guidelines for the effective diagnosis and treatment of ADHD.

In this parameter, the term "preschoolers" refers to children aged 3 through 5 years, "children" refers to children aged 6 through 12 years, and "adolescents" refers to minors aged 13 through 17 years. "Parent" refers to parent or legal guardian. "Patient" refers to any minor with ADHD. The terminology in this practice parameter is consistent with the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision (*DSM-IV-TR*) (American Psychiatric Association, 2000).

METHODOLOGY

The list of references for this parameter was developed by searching *PSYCInfo*, *Medline*, and *Psychological Abstracts*; by reviewing the bibliographies of book chapters and review articles; by asking colleagues for suggested source materials; and from the previous version of this parameter. The searches were conducted in September 2004 through April 2006 for articles in English using the key word "attention-deficit/hyperactivity disorder." The search covered the period 1996 to 2006 and yielded approximately 5,000 references. Recent authoritative reviews of literature, as well as recent treatment studies that were in press or that have been presented at scientific meetings in the past 2 to 3 years, were given priority for inclusion. The titles and abstracts of the remaining references were reviewed for particular relevance and selected for inclusion when the reference appeared to inform the field on the diagnosis and/or treatment of ADHD.

EPIDEMIOLOGY AND CLINICAL COURSE

Recently, epidemiological studies have more precisely defined the prevalence of ADHD and the extent of its treatment with medication. Rowland et al. (2002) surveyed more than 6,000 parents of elementary school children in a North Carolina county. Ten percent of the children had been given a diagnosis of ADHD and 7% were taking medication for ADHD. Parents of 2,800 third- through fifth-graders were surveyed in Rhode Island; 12% of parents reported that their child had been referred for evaluation and 6% were receiving medication (Harel and Brown, 2003). An epidemiological study of nearly 6,000 children in Rochester, Minnesota, found a cumulative incidence of ADHD in the elementary and secondary school population of 7.5% (95% confidence interval 6.5-8.4) (Barbarese et al., 2002), which was similar to a 6.7% prevalence of ADHD found by the U.S. National Health Interview Survey for the period 1997-2000 (Woodruff et al., 2004). The Centers for Disease Control (2005) conducted the National

Survey of Children's Health during January 2003-2004, asking parents of over 100,000 children aged four to 17 years whether their child had *ever* been diagnosed with ADHD or received medication treatment (as opposed to currently being treated). The rate of lifetime childhood diagnosis of ADHD was 7.8%, while 4.3% (or only 55% of those with ADHD) had ever been treated with medication for the disorder.

Follow-up studies have begun to delineate the life course of ADHD. A very large majority (60-85%) of children with ADHD will continue to meet criteria for the disorder during the teenage years (Barkley et al., 1990; Biederman et al., 1996; Claude and Firestone, 1995), clearly establishing that ADHD does not remit with the onset of puberty alone. Defining the number of children with ADHD who continue to have problems as adults is more difficult because of methodological issues reviewed by Barkley (2002). These include changes in informant (parent vs. child), use of different instruments to diagnose ADHD in adults, comorbidity of the other psychiatric disorders in the childhood sample (less comorbid samples have better outcome), and issues with the *DSM-IV* diagnostic criteria themselves. The criteria are designed for school-age children with regard to the number of symptoms required to meet the diagnostic threshold (i.e., six of the nine symptoms for inattention and/or hyperactivity/impulsivity), which may be developmentally inappropriate for adults. That is, an adult may suffer significant impairment even though he or she suffers from fewer than six of nine symptoms in these areas. The persistence of the full syndrome of ADHD in young adulthood has been found to range from 2% to 8% when self-report is used (Barkley et al., 2002; Mannuzza et al., 1993). In contrast, when parent report is used, the prevalence rises to 46% and when a developmental definition of disorder is used (98th percentile) it rises further to 67% (Barkley et al., 2002). Biederman et al. (2000) found that the rates of ADHD in adults varied according to number of symptoms and level of impairment required for the diagnostic threshold. While only 40% of 18- through 20-year-old "grown up" ADHD patients met the full criteria for ADHD, 90% had at least five symptoms of ADHD and a Global Assessment of Functioning score below 60. Faraone and Biederman (2005) performed telephone interviews with 966 adults and the prevalence of ADHD using narrow criteria (those who met full criteria and had childhood onset) was 2.9%, but 16.4% had subthreshold symptoms. Furthermore, adults with a childhood history of ADHD have higher than expected rates of antisocial and criminal behavior (Barkley et al., 2004), injuries and accidents (Barkley, 2004), employment and marital difficulties, health problems, and they are more likely to have teen pregnancies (Barkley et al., 2006) and children out of wedlock (Johnston, 2002). Recently, the National Comorbidity Survey Replication screened a probability sample of 3,199 individuals aged 19 through 44 years and estimated the prevalence of adult ADHD to be 4.4% (Kessler et al., 2005). Although this practice parameter concerns the assessment and treatment of the preschooler, child, or adolescent with ADHD, it is critical to note that many children with ADHD will continue to have impairment into adulthood that will require treatment.

COMORBIDITIES

It is well established that ADHD frequently is comorbid with other psychiatric disorders (Pliszka et al., 1999). Studies have shown that 54-84% of children and adolescents with ADHD may meet criteria for oppositional defiant disorder (ODD); a significant portion of these patients will develop conduct disorder (Barkley, 2005; Faraone et al., 1997). Fifteen to nineteen percent of patients with ADHD will start to smoke (Milberger et al., 1997) or develop other substance abuse disorders (Biederman et al., 1997). Depending on the precise psychometric definition,

25% to 35% of patients with ADHD will have a coexisting learning or language problem (Pliszka et al., 1999), and anxiety disorders occur in up to one-third of patients with ADHD (Biederman et al., 1991; MTA Cooperative Group, 1999b; Pliszka et al., 1999; Tannock, 2000). The prevalence of mood disorder in patients with ADHD is more controversial, with studies showing 0 to 33% of patients with ADHD meeting criteria for a depressive disorder (Pliszka et al., 1999). The prevalence of mania among patients with ADHD remains a contentious issue (Biederman, 1998; Klein et al., 1998). The National Institute of Mental Health (NIMH) Multimodal Treatment of ADHD (MTA) study (Jensen et al., 2001a) did not find it necessary to exclude any child with ADHD because of a diagnosis of bipolar disorder, but Biederman and colleagues (Biederman et al., 1992) found that 16% of a sample of ADHD patients met criteria for mania, although a chronic, irritable mania predominated. Comorbidity in adult ADHD patients is similar to that of children, except that antisocial personality replaces ODD or CD as the main behavioral psychopathology and mood disorders increase in prevalence (Biederman, 2004). Clinicians should be prepared to encounter a wide range of psychiatric symptoms in the course of managing patients with ADHD.

ETIOLOGY

Neuropsychological studies have shown that patients with ADHD have deficits in executive functions, which are “neurocognitive processes that maintain an appropriate problem solving set to attain a future goal” (p. 1336) (Willcutt et al., 2005). Specifically, a meta-analysis of 83 studies with more than 6,000 subjects showed that patients with ADHD have impairments in the executive functioning domains of response inhibition, vigilance, working memory, and some measures of planning (Willcutt et al., 2005). Nonetheless, not all patients with ADHD show executive function deficits, suggesting that while these deficits are a major factor in the disorder, other neuropsychological problems must be present as well. There is growing evidence that the principal cause of ADHD is genetic (Faraone et al., 2005b). Faraone et al. (2005b) reviewed 20 independent twin studies which estimated the heritability (the amount of phenotypic variance of symptoms attributed to genetic factors) to be 76%. Recent genome scan studies suggest ADHD is complex; ADHD has been associated with markers at chromosomes 4, 5, 6, 8, 11, 16, and 17 (Muenke, 2004; Smalley et al., 2004). Faraone et al. (2005b) identified eight genes in which the same variant was studied in three or more studies; seven of which showed statistically significant evidence of association with ADHD (the dopamine 4 and 5 receptors, the dopamine transporter, the enzyme dopamine beta hydroxylase, the serotonin transporter gene, the serotonin 1B receptor and the synaptosomal-associated protein-25 gene). Non-genetic causes of ADHD are also neurobiological in nature (Nigg, 2006), consisting of such factors as perinatal stress and low birth weight (Mick et al., 2002b), traumatic brain injury (Max et al., 1998), maternal smoking during pregnancy (Mick et al., 2002a) and very severe early deprivation (Kreppner et al., 2001). In the latter case, the deprivation must be extreme, as often occurs in institutional rearing or child maltreatment; there is no evidence that ordinary variations in child-rearing practices contribute to the etiology of ADHD.

Neuroimaging is a valuable research tool in the study of ADHD, but currently it is not useful for making a diagnosis of ADHD in clinical practice or in predicting treatment response (Zametkin et al., 2005). Children with ADHD have reduced cortical white and grey matter volume relative to controls, though there is much overlap between the groups. Furthermore, such volume deficits are more pronounced in treatment-naïve children with ADHD than in those

who have received long-term medication treatment (Castellanos et al., 2002). Sowell et al. (2003) also found decreased frontal and temporal lobe volume in children with ADHD relative to controls; grey matter deficits have also been found in the unaffected siblings of children with ADHD (Durstun et al., 2004). While the functional imaging of ADHD is in a preliminary stage, it has been shown that when patients with ADHD perform tasks requiring inhibitory control, differences in brain activation relative to controls have been found in the caudate, frontal lobes, and anterior cingulate (Bush et al., 2005).

RECENT ADVANCES IN TREATMENT

At the time of publication of the first AACAP practice parameter for ADHD in 1997 (American Academy of Child and Adolescent Psychiatry, 1997), the literature devoted to the treatment of ADHD was already voluminous. Stimulant treatment of ADHD was also the subject of an AACAP practice parameter (American Academy of Child and Adolescent Psychiatry, 2002). Most of that literature focused on the short-term treatment of ADHD, either with medication or psychosocial interventions. At the time of the first parameter, the intensive study of the pharmacokinetics and pharmacodynamics of stimulant medications was undertaken, pioneered by the group at the University of California at Irvine. Analog classroom settings were used to examine the hour by hour effects of stimulant medications on behavior and cognition and its relationship to serum stimulant medications (Swanson et al., 1998b, 2002b). Such studies lead to the development of Concerta® (Swanson et al., 1999a, 1998b, 2000, 2002a, 2003), Adderall XR® (Greenhill et al., 2003; McCracken et al., 2003), Metadate CD® (Swanson et al., 2004; Wigal et al., 2003) and Focalin ® (Quinn et al., 2004).

Subsequently, numerous large scale clinical trials prove the efficacy of these new agents (Biederman et al., 2002; Greenhill et al., 2002, 2005; McCracken et al., 2003; Pelham et al., 1999; Wigal et al., 2005; Wolraich, 2000; Wolraich et al., 2001), and atomoxetine (Michelson et al., 2001, 2003). A methylphenidate transdermal patch (Findling and Lopez, 2005; Pelham et al., 2005) has been recently approved for use. With these newer agents, efficacy has been established by rigorous, double-blind, placebo-controlled, multi-center trials. Longer-term, open-label studies of these agents, often lasting up to 2 years, have also been performed, giving the field more data about efficacy and safety after prolonged use.

The role of psychosocial interventions in the treatment of ADHD has also been much studied. The NIMH MTA study (MTA Cooperative Group, 1999a, 2004a) and the Multimodal Psychosocial Treatment study (M+MPT, also known as the New York/Montreal study) (Klein et al., 2004) have examined the unitary and combined effects of pharmacological and behavioral treatments on ADHD symptoms and its associated impairments in social and academic functioning. The MTA study has completed naturalistic follow-ups of their patients up to 22 months after ending the active study treatment phase (Jensen, 2005; Swanson, 2005). These large-scale, long-term, randomized clinical trials have greatly informed the field as to the efficacy of long-term medication treatment and the role of psychosocial interventions in ADHD. In particular, answers to the questions of when ADHD should be treated with pharmacological or behavioral therapy (or a combination of the two) can be based on empirical evidence.

EVIDENCE BASE FOR PRACTICE PARAMETERS

The AACAP develops both patient-oriented and clinician-oriented practice parameters. Patient-oriented parameters provide recommendations to guide clinicians toward the best

treatment practices. Treatment recommendations are based both on empirical evidence and clinical consensus, and are graded according to the strength of the empirical and clinical support. Clinician-oriented parameters provide clinicians with the information (stated as principles) needed to develop practice-based skills. Although empirical evidence may be available to support certain principles, principles are primarily based on expert opinion and clinical experience.

In this parameter, recommendations for best treatment practices are stated in accordance with the strength of the underlying empirical and/or clinical support, as follows:

- Minimal Standard [MS] is applied to recommendations that are based on rigorous empirical evidence (such as randomized, controlled trials) and/or overwhelming clinical consensus. Minimal standards apply more than 95% of the time; i.e., in almost all cases.
- Clinical Guideline [CG] is applied to recommendations that are based on strong empirical evidence (such as non-randomized controlled trials) and/or strong clinical consensus. Clinical guidelines apply approximately 75% of the time; i.e., in most cases.
- Option [OP] is applied to recommendations that are acceptable based on emerging empirical evidence (such as uncontrolled trials or case series/reports) or clinical opinion, but lack strong empirical evidence and/or strong clinical consensus.
- Not Endorsed [NE] is applied to practices that are known to be ineffective or contraindicated.

The strength of the empirical evidence is rated in descending order as follows:

- Randomized, controlled trial {rct} is applied to studies where subjects are randomly assigned to two or more treatment conditions
- Controlled trial {ct} is applied to studies where subjects are non-randomly assigned to two or more treatment conditions
- Uncontrolled trial {ut} is applied to studies where subjects are assigned to one treatment condition
- Case series/report {cs} is applied to a case series or a case report

SCREENING

Recommendation 1. *Screening for ADHD should be part of every patient's mental health assessment* [MS].

In any mental health assessment, the clinician should screen for ADHD by specifically asking questions regarding the major symptom domains of ADHD (inattention, impulsivity, and hyperactivity) and asking whether such symptoms cause impairment. These screening questions should be asked regardless of the nature of the chief complaint. Rating scales or specific questionnaires containing the *DSM* symptoms of ADHD can also be included in clinic/office registration materials to be filled out by parents before visits or in the waiting room before the evaluation. If a parent reports the patient suffers from any symptoms of ADHD that induce impairment, or if the patient scores in the clinical range for ADHD symptoms on a rating scale, then a full evaluation for ADHD as set out in the next recommendation is indicated.

EVALUATION

Recommendation 2. *Evaluation of the preschooler, child, or adolescent for ADHD should consist of clinical interviews with the parent and patient, obtaining information about the patient's school or day-care functioning, evaluation for comorbid psychiatric disorders, and review of the patient's medical, social, and family history [MS].*

The clinician should perform a detailed interview with the parent about each of the 18 ADHD symptoms listed in *DSM-IV*. For each symptom, the clinician should determine whether it is present, as well as its duration, severity, and frequency. Age at onset of the symptoms should be assessed. The patient must have the required number of symptoms (at least six of nine of the inattention cluster and/or at least six of nine of the hyperactive/impulsive criteria, each occurring more days than not), a chronic course (symptoms do not remit for weeks or months at a time), and onset of symptoms during childhood. After all the symptoms are assessed, the clinician should determine in which settings impairment occurs. Since most patients with ADHD have academic impairment, it is important to ask specific questions about this area. This is also an opportunity for the clinician to review the patient's academic/intellectual progress and look for symptoms of learning disorders. (See Recommendation 4.) Presence of impairment should be distinguished from presence of symptoms. For instance, a patient's ADHD symptoms may be observable only at school but not at home. Nonetheless, if the patient must spend an inordinate amount of time completing schoolwork in the evening that was not done in class, then impairment is present in two settings. *DSM-IV* requires impairment in at least two settings (home, school, or job) to meet criteria for the disorder, but clinical consensus agrees that severe impairment in one setting warrants treatment.

After reviewing the ADHD symptoms, the clinician should interview the parent regarding other common psychiatric disorders of childhood. Generally, it is most logical to next gather data from the parent regarding ODD and CD. Next, the clinician should explore whether the patient has symptoms of depression (and associated neurovegetative signs), mania, anxiety disorders, tic disorders, substance abuse, and psychosis, or evidence of a learning disability. Other practice parameters of the AACAP contain specific recommendations on eliciting symptoms of these disorders in children and adolescents. (See also Recommendation 5.)

The parent should fill out one of the many standardized behavior rating scales which have well-established normative values for children of a wide range of ages and genders. Scales in common use are listed in Table 1. These scales not only yield a measure of ADHD behaviors but tap into other psychiatric symptoms that could be comorbid with ADHD or might suggest an alternative psychiatric diagnosis. It is advisable for the clinician to request a release of information from the parent to obtain a similar rating scale from the patient's teacher(s). It is important to note that such rating scales do not by themselves diagnose ADHD, though parent or teacher ratings of inattention or hyperactivity/impulsivity that fall in the upper fifth percentile for the patient's age and gender are reason for serious concern. If the teacher cannot provide such a rating scale, or the parent declines permission to contact the school, materials from school, such as work samples or report cards, should be reviewed or inquired about.

Family history and family functioning should be assessed. As ADHD is highly heritable, a high prevalence of ADHD is likely to be found among the patient's parents and siblings. Family history of other significant mental disorders (affective, anxiety, tic, or conduct disorder) is helpful in determining the nature of any comorbid disorders, although a comorbid disorder should not be diagnosed solely on the basis of a family history of that comorbid disorder. Social

history of the family should be examined. As patients with ADHD perform better in structured settings, any factors in the family that create an inconsistent, disorganized environment may further impair the patient's functioning. Information regarding any physical or psychological trauma the patient may have experienced (including multiple visits to the emergency room) should be gathered, as well as any current psychosocial stressors.

The clinician should obtain information about the patient's perinatal history, developmental milestones, medical history, and mental health history (especially any prior psychiatric treatment). Delays in reaching developmental milestones or in social/language development suggest language disorders, mental retardation, or pervasive developmental disorders. Assessment of developmental milestones is particularly important in the evaluation of the preschooler, as many developmental disorders are associated with attention problems and hyperactivity.

The clinician should next interview the child or adolescent. For the preschool or young school-age child (aged 5-8 years), this interview may be done concurrently with the parent interview. Older children and adolescents should be interviewed separately from parents, as older children and teenagers may not reveal significant symptoms (depression, suicide, or drug or alcohol abuse) in the presence of a parent. Clinicians should be prepared to conduct a separate interview even with a younger child in many clinical situations, such as if the patient appears at risk for abuse or there is evidence of significant family dysfunction. The primary purpose of the interview with the child or adolescent is not to confirm or refute the diagnosis of ADHD. Young children are often unaware of their symptoms of ADHD, and older children and adolescents may be aware of symptoms but will minimize their significance. The interview with the child or adolescent allows the clinician to identify signs or symptoms inconsistent with ADHD or suggestive of other serious comorbid disorders. The clinician should perform a mental status examination, assessing appearance, sensorium, mood, affect, and thought processes. Through the interview process, the clinician develops a sense of whether the patient's vocabulary, thought processes, and content of thought are age-appropriate. Marked disturbances in mood, affect, sensorium, or thought process suggest the presence of psychiatric disorders other than or in addition to ADHD.

Recommendation 3. *If the patient's medical history is unremarkable, laboratory or neurological testing is not indicated* [NE].

There are few medical conditions that "masquerade" as ADHD, and the vast majority of patients with ADHD will have an unremarkable medical history. Children suffering a severe head injury may develop symptoms of ADHD, usually of the inattentive subtype. Encephalopathies generally produce other neurological symptoms (language or motor impairment) in addition to inattention. Hyperthyroidism, which can be associated with hyperactivity and agitation, rarely presents with ADHD symptoms alone but with other signs and symptoms of excessive thyroid hormone levels. The measurement of thyroid levels and thyroid stimulating hormone should be considered only if symptoms of hyperthyroidism other than increased activity level are present. Exposure to lead, either prenatally or during development, is associated with a number of neurocognitive impairments, including ADHD (Lidsky and Schneider, 2003). If a patient has been raised in an older, inner-city environment where exposure to lead paint or plumbing is probable, then serum lead levels should be considered. Serum lead level should not be part of routine screening. Children with fetal alcohol syndrome

or children exposed in utero to other toxic agents have a higher incidence of ADHD than the general population (O'Malley and Nanson, 2002).

Unless there is strong evidence of such factors in the medical history, neurological studies (electroencephalogram [EEG], magnetic resonance imaging, single photon emission computed tomography [SPECT], or positron emission tomography [PET]) are not indicated for the evaluation of ADHD. Specifically, the Council on Children, Adolescents and Their Families of the American Psychiatric Association has warned against the exposure of children to intravenous radioactive nucleotides as part of the diagnosis or treatment of childhood psychiatric disorders, citing both a lack of evidence for validity and safety issues (http://www.psych.org/psych_pract/clin_issues/populations/children/SPECT.pdf).

Recommendation 4. *Psychological and neuropsychological tests are not mandatory for the diagnosis for ADHD, but should be performed if the patient's history suggests low general cognitive ability or low achievement in language or mathematics relative to the patient's intellectual ability [OP].*

Low scores on standardized testing of academic achievement frequently characterize ADHD patients (Tannock, 2002). The clinician must determine if the academic impairment is secondary to the ADHD, if the patient has ADHD *and* a learning disorder, or if the patient has only a learning disorder and the patient's inattentiveness is secondary to the learning disorder. Academic impairment is commonly due to the ADHD itself. Many months or years of not listening in class, not mastering material in an organized fashion, and not practicing academic skills (not doing homework, etc.) leads to a decline in achievement relative to the patient's intellectual ability. If the parent and teacher report that the patient performs at (or even above) grade level on subjects when given one-to-one supervision (a patient can do all the problems on a test when held in from recess), then a formal learning disorder is less likely. In some cases the patient may engage in leisure activities that require the skill (e.g., reading science fiction novels) but avoid reading a history book in preparation for an exam. In such cases it is more appropriate to treat the ADHD and then determine whether the academic problems begin to resolve as the patient is more attentive in learning situations. On the other hand, if there is not clear evidence of an improvement in academic performance in 1 to 2 months despite improvement of the ADHD, then psychological testing for learning disorders is indicated.

In other cases, symptoms of learning/language disorders are present which cannot be accounted for by ADHD. These include deficits in expressive and receptive language, poor phonological processing, poor motor coordination, or difficulty grasping fundamental mathematical concepts. In such cases psychological testing will be needed to identify whether these deficits are related to a specific learning disorder. In the vast majority of cases, these learning disorders will be comorbid with the ADHD, and it is recommended strongly that the patient's ADHD be optimally treated before such testing. It could then be firmly concluded that any deficits identified are clearly the result of a learning disorder and not due to inattention to the test materials.

Purely learning-disordered patients are often inattentive when struggling with material in the area of their disability (a reading-disordered patient is inattentive when he/she must read) but do not have problems outside such a restricted academic setting. Patients with learning disorders alone do not show symptoms of impulsivity or hyperactivity. Children and adolescents with learning disorders may be oppositional with regard to schoolwork, and the clinician is consulted as to whether ADHD is the cause of the oppositional behavior. If a careful interview shows the

absence of full criteria for ADHD, and if the emergence of the oppositional behavior is clearly correlated with academic demands, then a primary learning disorder is more likely.

Psychological testing of the ADHD patient usually consists of a standardized assessment of intellectual ability (IQ), to determine any contribution of low general cognitive ability to the academic impairment, and academic achievement. Neuropsychological testing, speech/language assessments, and computerized testing of attention or inhibitory control are not required as part of a routine assessment for ADHD, but may be indicated by the findings of the standard psychological assessment.

Recommendation 5. *The clinician must evaluate the patient with ADHD for the presence of comorbid psychiatric disorders [MS].*

The clinician must integrate the data obtained with regard to comorbid symptoms to determine 1) whether the patient meets criteria for a separate comorbid disorder in addition to ADHD, 2) whether the comorbid disorder is the primary disorder and the patient's inattention or hyperactivity/impulsivity is directly caused by it, or 3) whether the comorbid symptoms do not meet criteria for a separate disorder but represent secondary symptoms stemming from the ADHD.

When patients with ADHD meet full *DSM-IV* criteria for a second disorder, the clinician should generally assume the patient has two or more disorders and develop a treatment plan to address each comorbid disorder in addition to the ADHD. Children with ADHD commonly meet criteria for ODD or CD. In young children, these disorders are nearly always present concurrently. Similarly, if a patient meets full *DSM-IV* criteria for major depressive disorder or a specific anxiety disorder, the clinician is most likely dealing with a comorbid disorder. Most often, the onset of the depressive disorder occurs several years after the onset of ADHD (Spencer et al., 1999), while anxiety disorders have an earlier onset concurrent with the ADHD (Kovacs and Devlin, 1998). A comorbid diagnosis of mania should be considered in ADHD patients who exhibit severe mood lability/elation/irritability, thought disturbances (grandiosity, flight of ideas), severe aggressive outbursts ("affective storms"), and decreased need for sleep or age-inappropriate levels of sexual interest. Mania should not be diagnosed solely on the basis of the severity of the ADHD symptoms or aggressive behavior in the absence of the manic symptoms listed above. Acutely manic ADHD patients generally require mood stabilization before treatment of the ADHD. The choice of a treatment regimen, particularly pharmacological intervention, is often influenced by the nature of the patient's comorbid disorder and which disorder is currently the most impairing of major life activities. Older adolescents with ADHD should be screened for substance abuse disorders, as they are at greater risk than teenagers without ADHD for smoking, alcohol and other illegal substance abuse disorders (Biederman et al., 1997; Wilens et al., 1997).

In other cases, another primary psychiatric disorder produces impairment of attention or impulse control. Impaired attention is caused by primary depressive/anxiety disorders, and those with primary mania have impaired impulse control and judgment. If a patient has no history of ADHD symptoms during childhood, but develops inattentiveness and poor concentration only *after* the onset of depression or mania, then the affective disorder is most likely primary. Patients with adolescent-onset ODD or CD are often described as impulsive or inattentive, but often do not meet full criteria for ADHD or had few ADHD symptoms in early childhood.

Finally, some associated problems may stem from the ADHD itself and not be a separate disorder. Patients with ADHD may develop associated symptoms of dysphoria or low self-

esteem secondary to the frustrations of living with ADHD. In such cases, the dysphoria is related specifically to the ADHD symptoms and there is an absence of pervasive depression, neurovegetative signs, or suicidal ideation. If such dysphoria is a result of the ADHD, then it should respond to successful treatment of the ADHD. The distractibility or impulsivity of ADHD patients may often be interpreted as oppositional behavior by caretakers or children. Mild mood lability (shouting out, crying easily, quick temper) is also common in ADHD. It is important to note that such associated symptoms do not reach the level of a separate *DSM* disorder, are temporally related to the onset of the ADHD, are often consistent with, though somewhat excessive, for the social context, and dissipate once the ADHD is successfully treated.

TREATMENT

Recommendation 6. *A well thought-out and comprehensive treatment plan should be developed for the patient with ADHD [MS].*

The patient's treatment plan should take account of ADHD as a chronic disorder and may consist of psychopharmacological and/or behavior therapy. This plan should take into account the most recent evidence concerning effective therapies, as well as family preferences and concerns. This plan should include parental and child psychoeducation about ADHD and its various treatment options (medication and behavior therapy), linkage with community supports, and additional school resources as appropriate. Psychoeducation is distinguished from psychosocial interventions such as behavior therapy. Psychoeducation is generally performed by the physician in the context of medication management and involves educating the parent and child about ADHD, helping parents anticipate developmental challenges that are difficult for ADHD children, and providing general advice to the parent and child to help improve the child's academic and behavioral functioning. The treatment plan should be reviewed regularly and modified if the patient's symptoms do not respond. Trade books, videos, and some noncommercial websites on ADHD may be useful adjunctive material to facilitate this step of treatment.

The short-term efficacy of psychopharmacological intervention for ADHD was well established at the time of the first AACAP practice parameter for ADHD (American Academy of Child and Adolescent Psychiatry, 1997). It is also clear that behavior therapy alone can produce improvement in ADHD symptoms relative to baseline symptoms or to wait-list controls (Pelham et al., 1998). Since then, a substantial focus has been on the relative efficacy of pharmacological therapy vs. psychosocial intervention. Jadad et al. (1999) reviewed 78 studies of the treatment of ADHD; 6 of these studies compared pharmacological to nonpharmacological interventions. The reviewers reported that studies consistently supported the superiority of stimulant over the non-drug treatment. Twenty studies compared combination therapy with a stimulant or psychosocial intervention, but no evidence of an additive benefit of combination therapy was found. Most of these studies involved short-term behavioral treatment; a major hypothesis in the early 1990s was that behavior therapy had to be administered for an extended time for patients with ADHD to realize its full benefit (Richters et al., 1995). Thus the MTA study was designed to look at comprehensive treatments provided over an entire year.

In the MTA study, children with ADHD were randomized to four groups: algorithmic medication treatment alone, psychosocial treatment alone, a combination of algorithmic medication management and psychosocial treatment, and community treatment. Algorithmic medication treatment consisted of monthly appointments in which the dose of medication was

carefully titrated according to parent and teacher rating scales. Children in all four treatment groups showed reduced symptoms of ADHD at 14 months relative to baseline. The two groups that received algorithmic medication management showed a superior outcome with regard to ADHD symptoms compared with those that received intensive behavioral treatment alone or community treatment (MTA Cooperative Group, 1999a {rct}). Those who received behavioral treatment alone were not significantly more improved than the group of community controls who received community treatment (two-thirds of the subjects in this group received stimulant treatment). The community treatment group had more limited physician follow-up and was treated with lower daily doses of stimulant compared with the algorithmic medication management group. Nearly a quarter of the subjects randomized to receive behavioral treatment alone required treatment with medication during the trial because of a lack of effectiveness of the behavioral treatment. It seems established that a pharmacological intervention for ADHD is more effective than a behavioral treatment alone.

This does not mean, however, that behavior therapy alone cannot be pursued for the treatment of ADHD in certain clinical situations. Behavior therapy might be recommended as an initial treatment if the patient's ADHD symptoms are mild with minimal impairment, the diagnosis of ADHD is uncertain, parents reject medication treatment or there is *marked* disagreement about the diagnosis between parents or between parents and teachers. Preference of the family should also be taken into account. A number of behavioral programs for the treatment of ADHD have been developed. Since the review by Pelham et al. (1998), a number of other controlled studies have shown short-term effectiveness of behavioral parent training (Chronis et al., 2004; Sonuga-Barke et al., 2001 {rct}, 2002 {rct}). Several manualized treatments for applying behavioral parent training to ADHD and ODD children are available (Barkley, 1997; Cunningham et al., 1997). Smith et al. (2006) provided an overview of the principles behind such programs. Generally, parents are involved in 10-20 sessions of 1-2 hours in which they are 1) given information about the nature of ADHD, 2) learn to attend more carefully to their child's misbehavior and to when their child complies, 3) establish a home token economy, 4) use time out effectively, 5) manage non compliant behaviors in public settings, 6) use a daily school report card, and 7) anticipate future misconduct. Occasional booster sessions are often recommended. Importantly, parental ADHD may interfere with the success of such programs (Sonuga-Barke et al., 2002), suggesting that treatment of an affected parent maybe an important part of the child's treatment. Generalized family dysfunction (parental depression, substance abuse, marital problems) may also need to be addressed in order that psychosocial or medication treatment is fully effective for the child with ADHD (Chronis et al., 2004).

The 1997 practice parameter (American Academy of Child and Adolescent Psychiatry, 1997) extensively reviewed a variety of non-pharmacological interventions for ADHD other than behavior therapy, including cognitive-behavioral therapy and dietary modification. No evidence was found at that time to support these interventions in patients with ADHD, and no studies have appeared since then that would justify their use. While there has been aggressive marketing of its use, the efficacy of EEG feedback, either as a primary treatment for ADHD or as an adjunct to medication treatment, has not been established (Loo, 2003). Formal social skills training for children with ADHD has not been shown to be effective (Antshel and Remer, 2003).

Recommendation 7. *The initial psychopharmacological treatment of ADHD should be a trial with an agent approved by the Food and Drug Administration (FDA) for the treatment of ADHD [MS].*

The following medications are approved by the FDA for the treatment of ADHD: dextroamphetamine (DEX), *d*- and *d,l*-methylphenidate (MPH), mixed salts amphetamine (MSA), and atomoxetine.

Stimulants

Many randomized clinical trials of stimulant medications have been performed in patients with ADHD over the past three decades. Stimulants are highly efficacious in the treatment of ADHD. In double-blind, placebo-controlled trials in both children and adults, 65% to 75% of subjects with ADHD have been determined to be clinical responders to stimulants, compared with 4% to 30% of subjects treated with placebo, depending on the response criteria used (Greenhill, 2002). When clinical response is assessed quantitatively via rating scales, the effect size of stimulant treatment relative to placebo is quite large, averaging about 1.0, one of the largest effects for any psychotropic medication. In the MTA study, subjects who responded to short-term placebo treatment did not maintain such gains and 90% of these subjects were subsequently treated with stimulants in the 14-month time frame of the study (Vitiello et al., 2001).

The physician is free to choose any of the two stimulant types (MPH or amphetamine), as evidence suggests the two are equally efficacious in the treatment of ADHD. Immediate-release stimulant medications have the disadvantage that they must be taken two to three times a day to control ADHD symptoms throughout the day. In the past 5 years, extensive trials have been carried out with long-acting forms of MPH (Concerta®, Daytrana®, Focalin-XR®, Metadate®, Ritalin LA®), MSA (Adderall XR®), and an amphetamine pro-drug lisdexamfetamine (Vyvanse®) (Biederman et al., 2002, 2006; Findling and Lopez, 2005; Greenhill et al., 2002, 2006b; McGough et al., 2006b; Wolraich et al., 2001). These long-acting formulations are equally efficacious as the immediate-release forms and have been shown to be efficacious in adolescents as well as children (Spencer et al., 2006; Wilens et al., 2006). They offer greater convenience for the patient and family and enhance confidentiality, as the school-age patient need not report to the school nurse for medication administration. Single daily dosing is associated with greater compliance for all types of medication, and long-acting MPH may improve driving performance in adolescents relative to short-acting MPH (Cox et al., 2004 {ret}). Physicians may use long-acting forms as initial treatment; there is no need to titrate to the appropriate dose on short-acting forms and then “transfer” children to a long-acting form. Short-acting stimulants are often used as initial treatment in very small children (<16 kg in weight), for whom there are no long-acting forms in a sufficiently low dose.

Typical dosing of the stimulant medications is shown in Table 2. The AACAP has also issued specific parameters for the use of stimulant medications (American Academy of Child and Adolescent Psychiatry, 2002). These doses represent guidelines; with careful clinical monitoring, these doses may be exceeded in individual cases. Studies of the treatment of adult ADHD shed light on the doses necessary to optimally treat adult-sized adolescents. Spencer et al. (2005 {ret}) conducted a 6-week double-blind, parallel-group study of MPH in 146 adults with ADHD. MPH was highly efficacious (76% response rate on MPH vs. 19% on placebo) at a mean oral dose of 1.1 mg/kg/day (mean daily dose 88 ± 22 mg). This would suggest that adult-

sized adolescents might need doses of MPH in this range (or the equivalent dose in amphetamine or Concerta®) to have an adequate response, but careful monitoring for side effects should be undertaken at such doses. There have not been any studies examining the effects of dosages of MPH or amphetamine in adolescents above 60 mg/day or 72 mg of Concerta®. Doses in this range should be used only with caution, with frequent monitoring of side effects. On average, there is a linear relationship between dose and clinical response: that is, in any group of ADHD subjects, more subjects will be classified as responders and there is a greater reduction in symptoms at the higher doses of stimulant. There is no evidence of a global “therapeutic” window in ADHD patients. Each patient, however, has a unique dose-response curve. If a full range of MPH doses are used, roughly a third of school-age patients will have an *initial* optimal response on a low (<15 mg/day), a medium (16-34 mg/day), or a high (>34 mg/day) daily dose (Vitiello et al., 2001 {rct}). Most, however, will require dose adjustment upward as treatment progresses.

After selecting the starting dose, the physician may titrate upward every 1 to 3 weeks until the maximum dose for the stimulant is reached, symptoms of ADHD remit, or side effects prevent further titration, whichever occurs first. Contact with physician or trained office staff during titrations is recommended. It is helpful to obtain teacher and parent rating scales after the patient has been observed by the adult on a selected dose for at least a week. The parent and the patient should be queried about side effects. An office visit should then be scheduled after the first month of treatment to review overall progress and determine whether the stimulant trial was a success and long-term maintenance on the particular stimulant should commence.

Arnold (2000) reviewed studies in which subjects underwent a trial of both amphetamine and MPH. This review suggested that approximately 41% of subjects with ADHD responded equally to both MPH and amphetamine, while 44% responded preferentially to one of the classes of stimulants. This suggests the initial response rate to stimulants may be as high as 85% if *both* stimulants are tried (in contrast to the finding of 65-75% response when only one stimulant is tried). There is at present, however, no method to predict which stimulant will produce the best response in a given patient. The titration schedule for DEX or MSA follows a similar practice as for MPH. Patients with ADHD and comorbid anxiety or disruptive behavior disorders have as robust a response of their ADHD symptoms to stimulants as do patients who do not have these comorbid conditions (MTA Cooperative Group, 1999b {rct}).

Treatment of preschoolers with stimulants

Stimulants have been widely prescribed by clinicians for this age group, though the number of published controlled trials is limited. Connor (2002) reviewed nine small studies of MPH in children under 6 years old, all of which used some type of blind as well as a crossover or parallel-group design. These studies involved 206 subjects and used doses of MPH that ranged from 2.5 to 30 mg/day, or 0.15 to 1.0 mg/kg/day. Eight of the nine studies supported the efficacy of MPH in the treatment of preschoolers with ADHD at milligram-per-kilogram doses that were comparable with those used in school-age children. Studies of preschoolers with significant developmental delays suggested this subgroup was prone to higher rates of side effects including social withdrawal, irritability, and crying (Handen et al., 1999 {rct}). Thus a cautious titration is recommended in this subgroup. In NIMH-funded Preschool ADHD Treatment Study (PATS), 183 children aged 3 to 5 years underwent an open-label trial of MPH; subsequently 165 of these subjects were randomized into a double-blind, placebo-controlled crossover trial of MPH lasting

6 weeks (Kollins et al., 2006). One hundred forty subjects who completed this second phase went on to enter a long-term maintenance study of MPH. Parents of subjects in this study were required to complete a 10 week course of parent training before their child was treated with medication. Of note, only 37 of 279 enrolled parents felt that the behavior training resulted in significant or satisfactory improvement (Greenhill et al., 2006a).

Results from the short-term, open-label run-in and double-blind crossover studies do show that MPH is effective in preschoolers with ADHD (Greenhill et al., 2006a). The mean optimal dose of MPH was found to be 0.7 ± 0.4 mg/kg/day, which is lower than the mean of 1.0 mg/kg/day found to be optimal in the MTA study with school-age children. Eleven per cent of subjects discontinued MPH because of adverse events (Wigal et al., 2006). Also relative to the MTA study, the preschool group showed a higher rate of emotional adverse events, including crabbiness, irritability, and proneness to crying. The conclusion was that the dose of MPH (or any stimulant) should be titrated more conservatively in preschoolers than in school-age patients, and lower mean doses may be effective. A pharmacokinetic study done as part of the PATS protocol showed that preschoolers metabolized MPH more slowly than did school-age children, perhaps explaining these results (McGough et al., 2006a).

Atomoxetine

Atomoxetine is a noradrenergic reuptake inhibitor that is superior to placebo in the treatment of ADHD in children, adolescents, and adults (Michelson et al., 2001 {rct}, 2002 {rct}, 2003 {rct}; Swensen et al., 2001 {rct}). Its effect size was calculated to be 0.7 in one study (Michelson et al., 2002). Atomoxetine can be given daily or twice a day, with the second dose given in the evening; atomoxetine may have less pronounced effects on appetite and sleep than stimulants, although they may produce relatively more nausea or sedation. Dosing of atomoxetine is shown in Table 2.

Michelson et al. (2002) showed that while atomoxetine was superior to placebo at week 1 of the trial, the greatest effects were observed at week 6, suggesting the patient should be maintained at the full therapeutic dose for at least several weeks in order to obtain the drug's full effect. Atomoxetine has been studied in the treatment of patients with ADHD and comorbid anxiety (Sumner et al., 2005 {rct}). Patients with ADHD or an anxiety disorder (generalized anxiety, separation anxiety, or social phobia) were randomized to either atomoxetine (n = 87) or placebo (n = 89) in a double-blind, placebo-controlled manner for 12 weeks of treatment. At the end of the treatment period, atomoxetine led to a significant reduction in ratings of symptoms of both ADHD and anxiety relative to placebo, showing the drug to be efficacious in the treatment of both conditions. This study is of interest because treatment algorithms for ADHD with comorbid anxiety have recommended treatment of ADHD first with stimulants, then addition of a selective serotonin reuptake inhibitor (SSRI) for treatment of the anxiety (Pliszka et al., 2000). Recently, however, the SSRI fluvoxamine was shown not to be superior to placebo for the treatment of anxiety when added to a stimulant in a small sample (n = 25) of children with ADHD and comorbid anxiety (Abikoff et al., 2005 {rct}). This small study does not invalidate this practice, but the above results of Sumner et al. (2005) suggest that using atomoxetine for the treatment of ADHD with comorbid anxiety is a viable, alternative approach. No evidence exists that atomoxetine is effective for the treatment of major depressive disorder, however.

Selection of agent

The clinician and family face the choice of which agent to use for the initial treatment of the patient with ADHD. The American Academy of Pediatrics (American Academy of Pediatrics, 2001), an international consensus statement (Kutcher et al., 2004), and the Texas Children's Medication Project (Pliszka et al., 2006a) have all recommended stimulants as the first line of treatment for ADHD, particularly when no comorbidity is present. Direct comparisons of the efficacy of atomoxetine to that of MPH (Michelson, 2004) and amphetamine (Wigal et al., 2004) have shown a greater treatment effect of the stimulants, and in a meta-analysis of atomoxetine and stimulant studies, the effect size for atomoxetine was 0.62 compared with 0.91 and 0.95 for immediate-release and long-acting stimulants, respectively (Faraone et al., 2003). However, atomoxetine may be considered as the first medication for ADHD in persons with an active substance abuse problem, comorbid anxiety, or tics. Atomoxetine is preferred if the patient experiences severe side effects to stimulants such as mood lability or tics (Biederman et al., 2004). When dosed twice a day, effects on late evening behavior may be seen.

It is the sole choice of the family and the clinician as to which agent should be used for the patient's treatment and each patient's treatment must be individualized. Nothing in these guidelines should be construed by third-party payers as justification for requiring a patient to be a treatment failure (or experience side effects) to one agent before allowing the trial of another.

Recommendation 8. *If none of the above agents results in satisfactory treatment of the patient with ADHD, the clinician should undertake a careful review of the diagnosis and then consider behavior therapy and/or the use of medications not approved by the FDA for the treatment of ADHD [CG].*

The vast majority of patients with ADHD who do not have significant comorbidity respond satisfactorily to the agents listed in recommendation 7. If a patient fails to respond to trials of all these agents after an adequate length of time at appropriate dosages for the agent as noted in Table 2, then the clinician should undertake a review of the patient's diagnosis of ADHD. This does *not* require the patient to be completely re-evaluated, but the clinician should be certain of the accuracy of the history that led to the diagnosis of ADHD and examine whether any undetected comorbid conditions are present, such as affective disorders, anxiety disorders, or subtle developmental disorders. The clinician should ascertain that these factors are not the primary problems impairing the patient's attention and impulse control. Primary care physicians should consider referral to a child and adolescent psychiatrist at this point.

Bupropion, tricyclic antidepressants (TCAs), and alpha-agonists are often used in the treatment of ADHD even though they are not approved by the FDA for this purpose. Although there is at least one double blind, randomized controlled trial for bupropion, TCAs and clonidine, the evidence base for these medications is far weaker than for the FDA-approved agents (Pliszka, 2003). Their dosages for clinical use are shown in Table 3. These agents may have effect sizes considerably less than that of the approved agents, and comparable with the effectiveness of behavior therapy (Pelham et al., 1998). Thus it may be prudent for the clinician to recommend a trial of behavior therapy at this point, before moving to these second-line agents. In other cases, the patient may have had a partial response to one of the FDA-approved agents, wherein there is definite improvement over baseline symptoms but impairment at home or school still is present. As noted in recommendation 12, addition of behavior therapy along with treatment with the FDA-approved agent may provide added benefit in such cases.

Bupropion, TCAs, and alpha-agonists, while not as extensively studied as the previously discussed medications, have shown effectiveness in small controlled trials or open trials. The common doses of these agents used in children and adolescents are shown in Table 3. Bupropion is a noradrenergic antidepressant which showed modest efficacy in the treatment of ADHD in one double-blind, placebo-controlled trial (Conners et al., 1996 {rct}). It is contraindicated in patients with a current seizure disorder. It can be given in both immediate-release and long-acting forms, but may not come in pill sizes small enough for children who weigh less than 25 kg.

TCA medications are the most studied of the non-FDA approved medications for the treatment of ADHD (Daly and Wilens, 1998 {rct}). Imipramine and nortriptyline have been most commonly used in recent years by clinicians. Among the TCAs, desipramine should be used with extreme caution in children and adolescents, as there have been reports of sudden death (Biederman et al., 1995; Riddle et al., 1993). Desipramine should be used only if other TCAs have not proven effective or have caused the patient to suffer excessive side effects. For TCAs, an electrocardiogram (ECG) must be done at baseline and after each dose increase. Once the patient is on a stable dose of the TCA, a plasma level should be obtained to ensure the level is not in the toxic range. On the other hand, if the level is subtherapeutic in terms of the range for the treatment of depression, there is no need to further increase the dose if the symptoms of ADHD are adequately controlled.

Alpha-agonists (clonidine and guanfacine) have been widely prescribed to patients with ADHD – for the disorder itself, for comorbid aggression, or to combat side effects of tics or insomnia. Extensive controlled trials of these agents are lacking. Connor et al. (1999) performed a meta-analysis of 11 studies of clonidine in the treatment of ADHD. The studies were highly variable in both method and outcome, and open-label studies showed a larger effect than controlled studies. Nevertheless, the review suggested a small to moderate effect size for clonidine in the treatment of ADHD. One small double-blind trial showed the superiority of guanfacine over placebo in the treatment of children with ADHD and comorbid tics (Scahill et al., 2001 {rct}). A gradual titration is required and clinical consensus suggests the alpha-agonists are more successful in treating hyperactive/impulsive symptoms than inattention symptoms, although this remains to be proven by clinical trials. In recent years, clinical consensus has led to the use of clonidine as adjunctive therapy to treat tics or stimulant-induced insomnia rather than as a primary treatment for ADHD. If the alpha-agonist is deemed ineffective after an adequate trial, the medication should be tapered gradually over 1 to 2 weeks to avoid a sudden increase in blood pressure.

Recommendation 9. *During a psychopharmacological intervention for ADHD, the patient should be monitored for treatment-emergent side effects [MS].*

For stimulant medications, the most common side effects are appetite decrease, weight loss, insomnia, or headache. Less common side effects of stimulants include tics and emotional lability/irritability. Treating physicians should be familiar with the precautions and reported adverse events contained in product labeling. Strategies for dealing with side effects include monitoring, dose adjustment of the stimulant, switching to another stimulant, and adjunctive pharmacotherapy to treat the side effects. If one of these side effects emerges, the physician should first assess the severity of the symptom and the burden it imposes on the patient. It is prudent to monitor side effects which do not compromise the patient's health or cause discomfort that interferes with functioning, as many side effects to stimulants are transient in nature and may

resolve without treatment. This approach is particularly valuable if the patient has had a robust behavioral response to the particular stimulant medication. If the side effect persists, reduction of dosage should be considered, although the physician may find that the dose which does not produce the side effect is not effective in the treatment of the ADHD. In this case, the physician should initiate a trial of a different stimulant or a nonstimulant medication.

After such trials, the physician, family, and patient may find that the one particular stimulant most efficacious in the treatment of that patient's ADHD also produces a troublesome side effect. In this case, adjunctive pharmacotherapy may be considered. Low doses of clonidine, trazodone, or an antihistamine are often helpful for stimulant-induced insomnia. Clinicians must be aware of the risk of priapism in males treated with trazodone (James and Mendelson, 2004). Some patients become paradoxically excited when treated with antihistamines; anticholinergic effects of some antihistamine agents can be detrimental. Melatonin in doses of 3 mg has recently been shown to be helpful in improving sleep in children with ADHD treated with stimulants (Tjon Pian Gi et al., 2003 {ut}). A chart review suggested cyproheptadine can attenuate stimulant-induced anorexia (Daviss and Scott, 2004 {cs}).

How often stimulants induce tics in patients with ADHD is less clear. Recent double-blind clinical trials of both immediate-release and long-acting stimulants have not found that stimulants increase the rate of tics relative to placebo (Biederman et al., 2002 {rct}; Wolraich et al., 2001 {rct}). Children with comorbid ADHD and tic disorders, on average, show a decline in tics when treated with a stimulant. This remains true even after more than a year of treatment (Gadow et al., 1999 {ut}; Gadow and Sverd, 1990). If a patient has treatment-emergent tics during a trial of a given stimulant, an alternative stimulant or a nonstimulant should be tried. If the patient's ADHD symptoms respond adequately only to a stimulant medication that induces tics, then combined pharmacotherapy of the stimulant and an alpha-agonist (clonidine or guanfacine) is recommended (The Tourette's Syndrome Study Group, 2002 {rct}).

Side effects of atomoxetine that occurred more often than placebo include gastrointestinal distress, sedation, and decreased appetite. These can generally be managed by dose adjustment, and while some attenuate with time, others such as headaches may persist (Greenhill et al., 2006c). If discomfort persists, the atomoxetine should be tapered off and a trial of a different medication initiated. On December 17, 2004, the FDA required a warning be added to atomoxetine because of reports that two patients (an adult and child) developed severe liver disease (both patients recovered). In the clinical trials of 6,000 patients, no evidence of hepatotoxicity was found. Patients who develop jaundice, dark urine, or other symptoms of hepatic disease should discontinue atomoxetine. Routine monitoring of hepatic function is not required during atomoxetine treatment.

Aggression, mood lability and suicidal ideation

Controlled trials of stimulants do not support the widespread belief that stimulant medications induce aggression. Indeed, overall aggressive acts and antisocial behavior decline when ADHD patients are treated with stimulants (Connor et al., 2002 {rct}). A rate of emotional lability of 8.6% was reported in patients taking Adderall XR® compared with a rate of 1.9% in the placebo group (Biederman et al., 2002). It should be noted, however, that this 4-week trial used an aggressive titration schedule and children were randomized to dose condition regardless of weight. The physician must distinguish between aggression/emotional lability that is present when the stimulant is active (i.e., during the day) and increased hyperactivity/impulsivity in the

evening when the stimulant is no longer effective. The latter phenomenon (commonly referred to as “rebound”) is more prevalent than the former, and it has been shown in laboratory classroom settings that even on placebo, the behavior of children with ADHD is worse in the late afternoon and evening than in the morning (Swanson et al., 1998a {rct}). Thus the “worsening” behavior observed by the caretaker in the evening was probably present before treatment, but is more noticeable compared with the now improved behavior during the day. The physician may deal with this situation by administering a dose of immediate-release stimulant in the late afternoon. Such a dose is usually smaller than one of the morning doses.

The FDA and its Pediatric Advisory Committee have reviewed data regarding psychiatric adverse events to medications for the treatment of ADHD (Food and Drug Administration, 2006). Data from both controlled trials and post-marketing safety data from sponsors and the FDA Adverse Events Reporting System (AERS), also referred to as MedWatch, was reviewed. For most of the agents, these events were slightly more common in the active drug group relative to placebo in the controlled trials, but with the exception of suicidal thinking with atomoxetine (see below) and modafinil these differences did not reach statistical significance (Mosholder, 2006). Post-marketing safety data was also reviewed for reports of mania/psychotic symptoms, aggression and suicidality (Gelperin, 2006). Such reports have many limitations, as information about dosage, comorbid diagnoses, and concomitant medications is often not available. Nonetheless, for each agent examined (all stimulants, atomoxetine, and modafinil) there were reports of rare events of toxic psychotic symptoms, specifically involving visual and tactile hallucinations of insects. Symptoms of aggression and suicidality (but no completed suicides) were also reported. At the time, the Pediatric Advisory Committee did not recommend a boxed warning regarding psychiatric adverse events, but did suggest clarifying labeling regarding these phenomena. No changes to the stimulant medication labeling were suggested regarding suicide or suicidal ideation.

In September of 2005, the FDA also issued an alert regarding suicidal thinking with atomoxetine in children and adolescents (Food and Drug Administration, 2005). In twelve controlled trials involving 1,357 patients on atomoxetine and 851 on placebo, the average risk of suicidal thinking was 4 per 1,000 in the atomoxetine-treated group vs. none in those on placebo. There was one suicide attempt in the atomoxetine group but no completed suicides. A boxed warning was added to the atomoxetine labeling. This risk is quite small, but it should be discussed with patients and family, and children should be monitored for the onset of suicidal thinking, particularly in the first few months of treatment.

If after starting an ADHD medication the patient clearly is more aggressive, emotionally labile or experiences psychotic symptoms, the physician should discontinue that medication and consider a different agent. Adjunctive therapy with neuroleptics or mood stabilizers is not recommended if the aggressive/labile behavior was not present at baseline and is clearly a side effect of the stimulant.

Cardiovascular issues

In March of 2006, the Pediatric Advisory Committee also addressed the risk of sudden death occurring with agents used for the treatment of ADHD (Villalaba, 2006). The FDA review of events related to sudden death revealed 20 sudden death cases with amphetamine or dextroamphetamine (14 child, 6 adult) while there were 14 pediatric and four adults cases of sudden death with MPH. It is important to note that the rate of sudden death in the general

pediatric population has been estimated at 1.3 to 8.5 per 100,000 patient-years (Liberthson, 1996). The rate of sudden death among those with a history of congenital heart disease can be as high as 6% by age 20 (Liberthson, 1996). Villalaba (2006) estimated the rate of sudden death in treated ADHD children for the exposure period January 1, 1992 to December 31, 2004 to be 0.2/100,000 patient-years for MPH, 0.3/100,000 patient-years for amphetamine and 0.5/100,000 patient-years for atomoxetine (the differences between the agents are not clinically meaningful). Thus the rate of sudden death of children on ADHD medications *do not* appear to exceed the base rate of sudden death in the general population. While an advisory committee one month earlier had recommended a boxed warning be issued for cardiovascular events, including stroke and myocardial infarction (Nissen, 2006), the Pediatric Advisory Committee did not support this recommendation. No evidence currently indicates a need for routine cardiac evaluation (i.e., ECG, echocardiogram) before starting any stimulant treatment in otherwise healthy individuals (Biederman et al., 2006). The package insert for stimulants states that these medications should generally not be used in children and adolescents with *pre-existing* heart disease or symptoms suggesting significant cardiovascular disease. This would include history of severe palpitations, fainting, exercise intolerance not accounted for by obesity, or strong family history of sudden death. Post operative tetralogy of Fallot, coronary artery abnormalities, and subaortic stenosis are known cardiac problems that require special considerations in using stimulants. Chest pain, arrhythmias, hypertension, or syncope may be signs of hypertrophic cardiomyopathy, which has been associated with sudden unexpected deaths in children and adolescents. Before a stimulant trial, such patients should be referred for consultation with a cardiologist for possible EKG and/or echocardiogram. If stimulants are initiated, the patient should also be followed by the cardiologists over the course of treatment.

Side effects of non FDA approved agents

Bupropion may cause mild insomnia or loss of appetite. Very high single doses (>400 mg) of bupropion may induce seizures even in patients without epilepsy. TCAs frequently cause anticholinergic side effects such as dry mouth, sedation, constipation, changes in vision, or tachycardia. Reduction in dosage or discontinuation of the TCA is often required if these side effects induce impairment. Side effects of alpha-agonists include sedation, dizziness, and possible hypotension. In the previous decade, there has been controversy over the safety of the use of alpha-agonists, particularly clonidine, in children. Swanson and colleagues (1995) noted about 20 case reports of children suffering significant changes in heart rate and blood pressure, particularly after clonidine dose adjustment. Four cases of death were reported in children taking a combination of MPH and clonidine, but there were many atypical aspects of these cases (Popper, 1995; Swanson et al., 1995, 1999b; Wilens and Spencer, 1999) and Wilens and Spencer (1999) doubted any causative relationship between the stimulant-agonist combination and the patients' deaths. There have been no further reports of severe cardiovascular adverse events associated with clonidine use in ADHD patients. Nonetheless, physicians must be cautious. The patient's blood pressure and pulse should be assessed periodically (Gutgesell et al., 1999), and abrupt discontinuations of the alpha-agonist are to be avoided. The patient and family should be advised to report any cardiac symptoms such as dizziness, fainting, or unexplained change in heart rate.

Recommendation 10. *If a patient with ADHD has a robust response to psychopharmacological treatment and subsequently shows normative functioning in academic, family, and social functioning, then psychopharmacological treatment of the ADHD alone is satisfactory [OP].*

Whether combined medication and psychosocial treatment of uncomplicated ADHD yields improved outcome relative to medication treatment alone remains a contentious issue. For children with ADHD alone, who do not have significant comorbidity, the MTA and M+MPT studies do not, for the most part, show an additive effect of the psychosocial interventions. In the first set of analyses of the MTA data, the four groups were compared over time on quantitative measures of ADHD symptoms; there was no significant difference between the comprehensive medication management group and the combined treatment group. In a subsequent set of analyses, an advantage for the combined treatment was seen. Swanson et al. (2001 {rct}) created a “categorical” outcome measure using the Swanson, Nolan, and Pelham (SNAP) behavior rating scale. Successful treatment was defined as having an average symptom rating no greater than 1.0 (“Just a little”). Using this definition, 68% of the combined group was optimally treated, compared with 56% of the medication-only group, a statistically significant difference. Behavioral treatment alone remained inferior to medication management, with only 34% of the behavioral treatment group maximally improved.

Combined treatment did not yield superior outcome to medication only in the M+MPT study. After 2 years of intensive psychosocial intervention and MPH, children with ADHD (without learning problems or comorbidities) were no different from those treated with medication alone in terms of ADHD symptoms (Abikoff et al., 2004b {rct}), academics (Hechtman et al., 2004 {rct}), or social skills (Abikoff et al., 2004a {rct}). Children in the MTA study were followed up 1 year after the end of active intervention. No benefit of combined treatment was found over medication alone, and stopping medication was strongly related to deterioration (MTA Cooperative Group, 2004a {rct}, 2004b {rct}). Overall, the data suggest that for ADHD patients without comorbidity who have a positive response to medication, adjunctive psychosocial intervention may not provide added benefit. Therefore, if a patient with ADHD shows full remission of symptoms and normative functioning, it is not mandatory that behavior therapy be added to the regimen, though parental preferences in this matter should be taken into account.

Recommendation 11. *If a patient with ADHD has a less than optimal response to medication, has a comorbid disorder, or experiences stressors in family life, then psychosocial treatment in conjunction with medication treatment is often beneficial [CG].*

In contrast to the lack of an additive effect of behavioral and pharmacological treatment in children with ADHD alone, the MTA study provided strong evidence that patients with ADHD and comorbid disorders and/or psychosocial stressors benefit from an adjunctive psychosocial intervention. Comorbid anxiety (as reported by the child’s parent) predicted a better response to behavioral treatment (March et al., 2000 {rct}), particularly when the ADHD patient had both an anxiety and a disruptive behavior disorder (ODD or CD) (Jensen et al., 2001b {rct}). Children receiving public assistance and ethnic minorities also showed a better outcome with combined treatment (Arnold et al., 2003 {rct}; MTA Cooperative Group, 1999b {rct}). Thus the clinician should individualize the psychosocial intervention for each ADHD patient, applying it in those patients who can most benefit because of comorbidity or the presence of psychosocial stress.

Recommendation 12. *Patients should be assessed periodically to determine if there is continued need for treatment or if symptoms have remitted. Treatment of ADHD should continue as long as symptoms remain present and cause impairment [MS].*

The patient with ADHD should have regular follow-up for medication adjustments to ensure that the medication is still effective, the dose is optimal, and side effects are clinically insignificant. For pharmacologic interventions, follow-up should occur at least several times a year. The number and frequency of psychosocial interventions should be individualized as well. The procedures performed at each office visit will vary according to clinical need, but over the course of annual treatment the clinician should review the child's behavioral and academic functioning, periodically assess height, weight, blood pressure and pulse, and assess for the emergence of comorbid disorders and medical conditions. Psychoeducation should be provided on an ongoing basis. The need to initiate formal behavior therapy should be assessed and the effectiveness of any current behavior therapy should be reviewed.

Medication treatment of ADHD now spans nearly 70 years, longer than antibiotic use (Bradley, 1937). The MTA clearly showed that once the study treatments ceased at 14 months, the combined and medication groups lost some of their treatment gains in part because of medication discontinuation and in part because the medication was now being given in the community with less careful monitoring and dose adjustment (MTA Cooperative Group, 2004a {rct}, 2004b {rct}). In contrast, in the M+MPT study, all the medication treatment was performed in the study. There was no deterioration in clinical effect or compliance, even in the second year, when the intensity of psychosocial treatment was greatly reduced (Abikoff et al., 2004b {rct}; Klein et al., 2004 {rct}). Given the high level of maladaptive behavior among adolescents with ADHD (Barkley et al., 2004), continued psychopharmacological intervention through this developmental period is likely to be highly beneficial. At the time of the 1997 AACAP practice parameter on ADHD, few long-term medication treatment studies of children with ADHD were available. One of the first controlled long-term stimulant studies studied the effects of DEX (Gillberg et al., 1997 {rct}). Children with ADHD (n = 62) were successfully treated with DEX in a short-term, open-label trial and then randomized to either placebo or DEX in a double-blind, parallel-group design for up to 1 year of treatment. Significantly more children relapsed in the placebo group (71%) than in the DEX group (29%), and the stimulant group showed significantly more improved ratings on the Conners Parent Rating Scales than the placebo group as the study progressed.

Charach et al. (2004) followed 79 of 91 participants from a clinical trial of MPH for an additional 5 years; 69 of these subjects remained in the study through year 5. Adherence to stimulant (defined as taking the medication at least 5 days a week since the last evaluation with no drug holidays that exceeded 14 weeks) was assessed at each year of the study. At 5 years, adherents showed greater improvement in teacher-reported symptoms than non-adherents; nonetheless, many subjects had discontinued their stimulant medication.

With the introduction of long acting stimulants and atomoxetine, longer term (1-2 year) open label follow-up safety studies have been performed. Caution needs to be used interpreting many of these studies due to their open label nature and high rates of attrition. Follow-up data from long-term, open-label Concerta® studies are available from both the first (Wilens et al., 2003a {ut}) and second year of treatment (Wilens et al., 2005 {ut}). In these studies, 497 children aged 6 through 13 years who had participated in double-blind, placebo-controlled studies of Concerta® were followed regularly over the study period. Patients received

adjustment of their daily dose of Concerta® according to clinical need. Teacher and Parent Inattention/Overactivity With Aggression (IOWA) Conners Rating Scales were obtained monthly in year 1, and in year 2 global evaluations of the effectiveness of the Concerta® were done by parents and teachers every 3 months. In year 1, the subjects' mean Inattention/Overactivity and Aggression/Defiance ratings done by both parents and teachers remained in the normative range throughout the study period. The mean prescribed dose of Concerta® rose from 35 mg to 41 mg by the end of year 1. Thirty-one subjects (7.6%) discontinued because of lack of effectiveness. Overall, 289 subjects completed year 1 of treatment. Two hundred twenty-nine subjects completed year 2; none of these dropped out because of lack of efficacy. Using the last observation carried forward, 85% of parents rated the effectiveness of the medication at the study's end as good or excellent.

A twenty-four month follow-up study of Adderall XR® showed similar long-term effectiveness (McGough et al., 2005 {ut}). Subjects (n = 568) began treatment with Adderall XR® with 10 mg daily, and investigators individually titrated doses up to a maximum of 30 mg/day; 273 (48%) completed treatment. By 24 months, the mean dose of Adderall XR® was 22.4 ± 6.9 mg. Each quarter of the study period, subjects' parents completed the 10-item Conners Parent Rating Scales; these ratings remained in the normative range throughout the 2-year period.

Long-term atomoxetine treatment was studied in 416 patients aged 6 through 15 years (Michelson et al., 2004 {ut}). Patients were treated in an open-label study of atomoxetine for 12 weeks; then they were randomized to either placebo or atomoxetine for 9 months. Atomoxetine was superior to placebo in preventing relapse, with 22.3% of atomoxetine subjects showing a return to baseline severity vs. 37.9% in the placebo group. Wilens et al. (2004 {ut}) reported on the follow-up of 601 adolescents with ADHD treated with atomoxetine, of whom 219 had completed 2 years of treatment. Subjects took doses of atomoxetine beginning at 1.2 and 2.0 mg/kg/day with a mean dose of 1.4 mg/kg/day. Ninety-nine (16.5%) discontinued the atomoxetine because of a lack of efficacy. Mean Parent ADHD Rating Scale-IV scores (assessed every 3 months) for the group fell into the normative range by the third month of treatment and remained until the end of the study.

Recent controlled trials of long-acting stimulants have confirmed the lack of any major medical adverse events with this class of medications, with no short term abnormalities of hematological or chemical measures (Biederman et al., 2002 {rct}; Greenhill et al., 2002 {rct}; McCracken et al., 2003 {rct}; Wolraich, 2000 {rct}; Wolraich et al., 2001 {rct}). While stimulants are a controlled substance, a meta-analysis of open-label long-term studies of stimulant treatment in ADHD concluded that stimulant treatment does not increase the risk of substance abuse and may even have a protective effect (Wilens et al., 2003b). Side effects that tend to persist in long-term treatment with all stimulants include insomnia, decreased appetite and/or weight loss, and headache (Charach et al., 2004 {ut}; Gillberg et al., 1997 {rct}; McGough et al., 2005 {ut}; Wilens et al., 2005 {ut}). In the long-term Adderall XR® study (McGough et al., 2005), 84 patients (15%) discontinued medication because of side effects. In the 2-year Concerta® study, 28 (6.9%) discontinued the study because of side effects in the first year, and an additional 3 subjects did so in the second year (Wilens et al., 2005). Two studies (Gillberg et al., 1997; Law and Schachar, 1999 {rct}) compared outcomes from children with ADHD treated with stimulant or placebo over a 6-month period. Neither study showed that DEX or MPH produced tics at a rate exceeding that of placebo. Gillberg et al. (1997) did not find that DEX-treated children have higher rates of anxiety or depression than those on placebo after 6

months of treatment. While side effects to medications used in the long-term treatment of ADHD can be problematic and require the attention of the clinician when they occur, they are without serious medical sequelae, of mild to moderate intensity, and generally respond to dose adjustment or change of medication.

As patients with ADHD enter late adolescence, clinicians and the family face the question of whether symptoms of ADHD and social functioning have improved to the point that medication intervention is no longer needed. Long term follow-up of MTA subjects (now followed for eight years after they started treatment with data analyzed at the two-year follow-up point published) have begun to shed some light on this issue. Subjects showed marked improvement during the first 14 months of the active study period, with more gradual improvement thereafter (Jensen, 2005 {ut}). Children who continued to be impaired were more likely to have ODD or CD, both at baseline and at follow-up. For the entire MTA group, treatment group effects (medication vs. no medication, combined treatment vs. medication alone) at 22 months were no longer significant. Secondary analyses of these data were performed to explore possible reasons for the loss of the effectiveness of the MTA medication management over the longer period of time (Swanson, 2005 {ut}). These analyses found that the ADHD sample fell into three groups: 1) children with initial small improvements followed by gradual improvement over time, 2) those with a large initial improvement who maintained improvement over the 36 months, and 3) children who showed initial improvement but then deteriorated. This third group had higher levels of aggression and lower IQ's at baseline. Medication effects on functioning were significant at follow-up only in the first two groups. The first group showed improved performance if they were on medication at follow-up, while the second showed more improvement if they had received the MTA medication titration algorithm at the start of treatment. Interestingly, in the second group current medication status did not affect outcome, meaning some children maintained gains even though they were no longer on medication. This implies that the clinician must be alert to the fact that some patients with ADHD deteriorate in spite of medication (and these are more likely to have comorbidity at baseline) while others do show remission of symptoms and may no longer require medication management.

If a patient with ADHD has been symptom-free for at least a year, then inquiries should be made if the patient and family still feel the medication provides a benefit. Signs that the ADHD has remitted include lack of any need to adjust dose despite robust growth, lack of deterioration when a dose of stimulant medication is missed, or new-found abilities to concentrate during drug holidays. Low stress times such as vacations are a good time to attempt a withdrawal from medication, but parents should assign some cognitively demanding tasks (reading a book, practicing mathematics problems) to be sure that remission has occurred. The start of a new school year is not a good time to attempt a drug holiday, but once a patient's school routine is established, the medication can be withdrawn and teacher input solicited. Medication should be re-instituted if the patient, parents or teachers report deterioration in functioning.

Recommendation 13. *Patients treated with medication for ADHD should have their height and weight monitored throughout treatment [MS].*

The effect of stimulant treatment on growth has been a concern for many years. The 1997 practice parameter on ADHD noted that stimulants were associated with small decreases in expected height and weight gain, which were rarely clinically significant (American Academy of Child and Adolescent Psychiatry, 1997). In the late 1990s, concern about effects on growth

abated, particularly since follow-up studies did not show any long term effect on ultimate adult height (Gittelman-Klein and Mannuzza, 1988; Kramer et al., 2000; Weiss and Hechtman, 2003). Recently, however, two major reviews (Faraone et al., 2006; Poulton, 2005) have examined all of the available data and concluded that stimulant treatment may be associated with a reduction in expected height gain, at least in the first 1-3 years of treatment. It is difficult to determine the clinical significance of such changes. The MTA study showed reduced growth rates in ADHD patients after 2 years of stimulant treatment compared with those patients who received no medication (MTA Cooperative Group, 2004b {rct}) and these deficits persisted at 36 months (MTA Cooperative Group, 2006 {rct}). The PATS study followed a group of 140 preschoolers who received MPH for up to a year for ADHD (Swanson et al., 2006 {rct}). The subjects had less than expected mean gains in height (-1.38 cm) and weight (-1.3 kg). Interestingly, in both the PATS and MTA studies, ADHD subjects were larger than average (~ .2 standard deviations above the mean) for both height and weight compared to controls or normative data prior to entry into the study, especially for treatment naïve subjects. Swanson et al. (2006 {rct}) hypothesized that children with ADHD are bigger, on average, than an age-matched sample of children without ADHD. Thus clinicians may not observe growth deficits in stimulant treated children because treatment does not slow the height acquisition rate enough to bring them below the mean for height for age. In a review and analysis of cross-sectional data, Spencer et al. (1996) compared the heights of ADHD patients to controls in three separate age samples. He found no height deficits relative to controls in childhood, a small but statistically significant reduction in height relative to controls at puberty, but no difference in height at adulthood. There was no relationship between stimulant treatment and height measures, and Spencer et al. (1996) hypothesized that ADHD itself was associated with a slower tempo of growth which resolved by adulthood, and the shorter stature was unrelated to medication effects. There is also evidence that stimulant induced growth delays are greater in the first year of treatment but attenuate after that (Faraone et al., 2005a; Spencer, 2003). Charach et al. (2006) found higher doses of stimulant correlated with reduced gains in height and weight, indeed the effect did not become significant until the dose in MPH equivalents was > 2.5 mg/kg/day for four years. Pliszka et al. (2006b) did not find that children with ADHD treated with monotherapy with either AMP or MPH showed any failure to achieve expected height; furthermore the two stimulant classes did not have any differential effect on height, but AMP had somewhat greater effects on weight than MPH. The subjects in this study had drug holidays averaging 31% of time during their treatment course, which may have contributed to the lack of effect of the stimulant on height.

In assessing for clinically significant growth reduction, it is recommended to use serial plotting of height and weight on growth charts labeled with lines showing the major percentiles (5th, 10th, 25th, 50th, 75th, 90th, and 95th) (Mei et al., 2004). This should occur 1-2 times per year, and more frequently if practical. If the patient has a change in height or weight that crosses 2 percentile lines, this suggests an aberrant growth trajectory. In these cases, a drug holiday should be considered, if return of symptoms during weekends or summers does not lead to marked impairment of functioning. The clinician should also consider switching the patient to another ADHD medication. It is important for the clinician to carefully balance the benefits of medication treatment with the risks of small reductions in height gain, which as of yet have not shown to be related to reductions in adult height (Gittelman-Klein and Mannuzza, 1988; Kramer et al., 2000; Weiss and Hechtman, 2003).

SUMMARY

The key to effective long-term management of the patient with ADHD is continuity of care with a clinician experienced in the treatment of ADHD. The frequency and duration of follow-up sessions should be individualized for each family and patient, depending on the severity of ADHD symptoms, the degree of comorbidity of other psychiatric illness, the response to treatment, and the degree of impairment in home, school, work, or peer-related activities. The clinician should establish an effective mechanism for receiving feedback from the family and other important informants in the patient's environment to be sure symptoms are well controlled and side effects minimal. While this parameter does not seek to set a formula for the method of follow-up, significant contact with the clinician should typically occur two to four times a year in cases of uncomplicated ADHD and up to weekly sessions at times of severe dysfunction or complications of treatment. Nothing in this parameter should be construed as justification for limiting clinician contact by third-party payers or for regarding more limited contact by the clinician as substandard when clinical evidence documents that the patient is functioning well.

PARAMETER LIMITATIONS

AACAP practice parameters are developed to assist clinicians in psychiatric decision-making. These parameters are not intended to define the standard of care; nor should they be deemed inclusive of all proper methods of care or exclusive of other methods of care directed at obtaining the desired results. The ultimate judgment regarding the care of a particular patient must be made by the clinician in light of all the circumstances presented by the patient and his/her family, the diagnostic and treatment options available, and available resources.

Disclosure: Steven Pliszka, M.D., author, receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Shire Pharmaceuticals Group plc, McNeil Pediatrics, and Eli Lilly and Company. Oscar Bukstein, M.D., co-chair, receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Cephalon, Inc., Forest Pharmaceuticals, Inc., McNeil Pediatrics, Shire Pharmaceuticals Group plc, Eli Lilly and Company, and Novartis Pharmaceuticals Corporation.. William Bernet, M.D. and Heather Walter, M.D., co-chairs, have no financial relationships to disclose.

American Academy of Child and Adolescent Psychiatry

Table 1. Common behavior rating scales used in the assessment of ADHD and monitoring of treatment.	
Name of scale	Reference
Academic Performance Rating Scale (APRS)	The APRS is a 19-item scale for determining a child's academic productivity and accuracy in grades 1-6 that has 6 scale points; construct, concurrent, and discriminant validity data, as well as norms (n = 247), available (Barkley, 1990)
ADHD Rating Scale-IV	The ADHD Rating Scale-IV is an 18-item scale using <i>DSM-IV</i> criteria (DuPaul et al., 1998)
Brown ADD Rating Scales for Children, Adolescents and Adults	Psychological Corporation, San Antonio, TX (2001) http://www.drthomasebrown.com/assess_tools/index.html (Brown, 2001)
Child Behavior Checklist (CBCL)	Parent-completed CBCL and Teacher-Completed Teacher Report Form (TRF) http://www.aseba.org/index.html
Conners Parent Rating Scale-Revised (CPRS-R) The longer form should be used for initial assessment, while the shorter form is often used for assessing response to treatment, particularly when repeated administration is required.	Parent, adolescent self-report versions available (Conners, 1997)
Conners Teacher Rating Scale-Revised (CTRS-R) (See comment above)	(Conners, 1997)
Conners Wells Adolescent Self Report Scale	(Conners and Wells, 1997)
Home Situations Questionnaire-Revised (HSQ-R), School Situations Questionnaire-Revised (SSQ-R)	The HSQ-R is a 14-item scale designed to assess specific problems with attention and concentration across a variety of home and public situations; it uses a 0-9 scale and has test-retest, internal consistency, construct validity, discriminant validity, concurrent validity, and norms (n = 581) available (Barkley, 1990)
Inattention/Overactivity With Aggression (IOWA) Conners Teacher Rating Scale	The IOWA Conners is a 10-item scale developed to separate the inattention and overactivity ratings from oppositional defiance (Loney and Milich, 1982)
Swanson, Nolan, and Pelham (SNAP-IV) and SKAMP Internet site ADHD.NET	The SNAP-IV (Swanson, 1992) is a 26-item scale that contains <i>DSM-IV</i> criteria for ADHD and screens for other <i>DSM</i> diagnoses; the SKAMP (Wigal et al., 1998) is a 10-item scale that measures impairment of functioning at home and at school
Vanderbilt ADHD Diagnostic Parent and Teacher Scales	Teachers rate 35 symptoms and 8 performance items measuring ADHD symptoms and common comorbid conditions (Wolraich et al., 2003a). The parent version contains all 18 ADHD symptoms with items assessing comorbid conditions and performance (Wolraich et al., 2003b)

Table 2. Medications Approved by FDA for ADHD (alphabetical by class)					
GENERIC CLASS <i>Brand Name</i>	DOSAGE FORM	TYPICAL STARTING DOSE	FDA MAX/DAY	OFF-LABEL MAX/DAY	COMMENTS
AMPHETAMINE PREPARATIONS					
Short-acting					> Short-acting stimulants often used as initial treatment in small children (< 16 kg) but have disadvantage of bid-tid dosing to control symptoms throughout day > Longer-acting stimulants offer greater convenience, confidentiality, and compliance with single daily dosing but may have greater problematic effects on evening appetite and sleep > Adderall XR cap may be opened and sprinkled on soft food
<i>Adderall*</i>	5, 7.5, 10, 12.5, 15, 20, 30 mg	3-5 yr: 2.5 mg qd ≥ 6 yr: 5 mg qd-bid	40 mg	> 50 kg: 60 mg	
<i>Dexedrine*</i>	5 mg	3-5 yr: 2.5 mg qd			
<i>DextroStat*</i>	5, 10 mg	≥ 6 yr: 5 mg qd-bid			
Long-acting					
<i>Dexedrine Spansule</i>	5, 10, 15 mg	≥ 6 yr: 5-10 mg qd-bid	40 mg	> 50 kg: 60 mg	
<i>Adderall XR</i>	5, 10, 15, 20, 25, 30 mg	≥ 6 yr: 10 mg qd	30 mg	> 50 kg: 60 mg	
<i>lisdexamfetamine</i>	30, 50, 70 mg	30 mg qd	70 mg	Not yet known	
METHYLPHENIDATE PREPARATIONS					
Short-acting					> Short-acting stimulants often used as initial treatment in small children (< 16 kg) but have disadvantage of bid-tid dosing to control symptoms throughout day > Longer-acting stimulants offer greater convenience, confidentiality, and compliance with single daily dosing but may have greater problematic effects on evening appetite and sleep > Metadate CD and Ritalin LA caps may be opened and sprinkled on soft food
<i>Focalin</i>	2.5, 5, 10 mg	2.5 mg bid	20 mg	50 mg	
<i>Methylin*</i>	5, 10, 20 mg	5 mg bid	60 mg	> 50 kg: 100 mg	
<i>Ritalin*</i>					
Intermediate-acting					
<i>Metadate ER</i>	10, 20 mg	10 mg q am	60 mg	> 50 kg: 100 mg	

<i>Methylin ER</i>	10, 20 mg				
<i>Ritalin SR*</i>	20 mg				
<i>Metadate CD</i>	10, 20, 30, 40, 50, 60 mg	20 mg q am	60 mg	> 50 kg: 100 mg	
<i>Ritalin LA</i>	10, 20, 30, 40 mg				
Long-acting					
<i>Concerta</i>	18, 27, 36, 54 mg	18 mg q am	72 mg	108 mg	> Swallow whole with liquids > Nonabsorbable tablet shell may be seen in stool.
<i>Daytrana Patch</i>	10, 15, 20, 30 mg patches	Begin with 10 mg patch qd, then titrate up by patch strength	30 mg	Not yet known	
<i>Focalin XR</i>	5, 10, 15, 20 mg	5 mg q am	30 mg	50 mg	
SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR					
Atomoxetine					> Not a schedule II medication > Consider if active substance abuse or severe side effects of stimulants (mood lability, tics) > Give qam or divided doses bid (effects on late evening behavior) > Do not open capsule > Monitor closely for suicidal thinking and behavior, clinical worsening, or unusual changes in behavior
<i>Strattera</i>	10, 18, 25, 40, 60, 80, 100 mg	Children and adolescents < 70 kg: 0.5 mg/kg/day for 4 days; then 1 mg/kg/day for 4 days; then 1.2 mg/kg/day	Lesser of 1.4 mg/kg or 100 mg	Lesser of 1.8 mg/kg or 100 mg	
* generic formulation available					

1
2

1

Table 3. Medications Used for ADHD, Not Approved by FDA				
GENERIC CLASS <i>Brand Name</i>	DOSAGE FORM	TYPICAL STARTING DOSE	MAX/DAY	COMMENTS
ANTIDEPRESSANTS				
Bupropion				> Lowers seizure threshold; contraindicated if current seizure disorder > Usually given in divided doses, bid for children, tid for adolescents, for both safety and effectiveness
<i>Wellbutrin*</i>	75, 100 mg tab	Lesser of 3 mg/kg/day or 150 mg/day	Lesser of 6 mg/kg or 300 mg, with no single dose > 150 mg	
<i>Wellbutrin SR</i>	100, 150, 200 mg tab			
<i>Wellbutrin XL</i>	150, 300 mg tab			
Imipramine				> Obtain baseline ECG before starting imipramine and nortriptyline
<i>Tofranil*</i>	10, 25, 50, 75 mg tab	1 mg/kg/day	Lesser of 4 mg/kg or 200 mg	
Nortriptyline				
<i>Pamelor*</i> , <i>Aventil*</i>	10, 25, 50, 75 mg cap	0.5 mg/kg/day	Lesser of 2 mg/kg or 100 mg	
ALPHA-2-ADRENERGIC AGONISTS				
Clonidine				> May be used alone or as adjuvant to another medication for ADHD > Effective for impulsivity and hyperactivity; modulating mood level; tics worsening from stimulants; sleep disturbances
<i>Catapres*</i>	0.1, 0.2, 0.3 mg tab	< 45 kg: 0.05 mg qhs; titrate in 0.05 mg increments bid, tid, qid > 45 kg: 0.1 mg qhs; titrate in 0.1 mg increments bid, tid, qid	27-40.5 kg: 0.2 mg 40.5- 45 kg: 0.3 mg > 45 kg: 0.4 mg	
Guanfacine				> May not see effects for 4-6 weeks > Review personal and family cardiovascular history > Taper off to avoid rebound hypertension
<i>Tenex*</i>	1, 2 mg tab	< 45 kg: 0.5 mg qhs; titrate in 0.5 mg increments bid, tid, qid > 45 kg: 1 mg qhs; titrate in 1 mg increments bid, tid, qid	27-40.5 kg: 2 mg 40.5- 45 kg: 3 mg > 45 kg: 4 mg	
* generic formulation available				

2

3

1 REFERENCES

- 2
- 3 Abikoff H, Hechtman L, Klein RG, Gallagher R, Fleiss K, Etcovitch J, Cousins L, Greenfield B,
4 Martin D, Pollack S (2004a), Social functioning in children with ADHD treated with
5 long-term methylphenidate and multimodal psychosocial treatment. *J Am Acad Child*
6 *Adolesc Psychiatry* 43:820-829
- 7 Abikoff H, Hechtman L, Klein RG, Weiss G, Fleiss K, Etcovitch J, Cousins L, Greenfield B,
8 Martin D, Pollack S (2004b), Symptomatic improvement in children with ADHD treated
9 with long-term methylphenidate and multimodal psychosocial treatment. *J Am Acad*
10 *Child Adolesc Psychiatry* 43:802-811
- 11 Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, Riddle M, Oatis M,
12 Greenhill L, Skrobala A, March J, Gammon P, Robinson J, Lazell R, McMahon DJ, Ritz
13 L (2005), Sequential pharmacotherapy for children with comorbid attention-
14 deficit/hyperactivity and anxiety disorders. *J Am Acad Child Adolesc Psychiatry* 44:418-
15 427
- 16 American Academy of Child and Adolescent Psychiatry (1997), Practice parameters for the
17 assessment and treatment of children, adolescents, and adults with attention-
18 deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 36:85S-121S
- 19 American Academy of Child and Adolescent Psychiatry (2002), Practice parameter for the use of
20 stimulant medications in the treatment of children, adolescents, and adults. *J Am Acad*
21 *Child Adolesc Psychiatry* 41:26S-49S
- 22 American Academy of Pediatrics (2001), Clinical practice guideline: treatment of the school-
23 aged child with attention-deficit/hyperactivity disorder. *Pediatrics* 108:1033-1044
- 24 American Psychiatric Association (2000), *Diagnostic and Statistical Manual of Mental*
25 *Disorders - Fourth Edition (Text revision) (DSM-IV-TR)*. Washington, DC: American
26 Psychiatric Association
- 27 Antshel KM, Remer R (2003), Social skills training in children with attention deficit
28 hyperactivity disorder: a randomized-controlled clinical trial. *J Clin Child Adolesc*
29 *Psychol* 32:153-165
- 30 Arnold LE (2000), Methylphenidate vs. amphetamine: comparative review. *J Atten Disord*
31 3:200-211
- 32 Arnold LE, Elliot M, Sachs L, Bird H, Kraemer HC, Wells KC, Abikoff HB, Comarda A,
33 Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hindshaw SP, Hoza B, Jensen PS,
34 March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wigal T
35 (2003), Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-
36 month outcome in ADHD. *J Consult Clin Psychol* 71:713-727
- 37 Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, Mrazek DA,
38 Jacobsen SJ (2002), How common is attention-deficit/hyperactivity disorder? Incidence
39 in a population-based birth cohort in Rochester, Minn. *Arch Pediatr Adolesc Med*
40 156:217-224
- 41 Barkley RA (1990), *Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and*
42 *Treatment*. New York: The Guilford Press
- 43 Barkley RA (1997), *Defiant Children: A Clinician's Manual for Assessment and Parent*
44 *Training*. New York: Guilford Press

- 1 Barkley RA (2002), ADHD - long term course, adult outcome, and comorbid disorders. In:
2 *Attention Deficit Hyperactivity Disorder: State of the Science, Best Practices*, Jensen PS,
3 Cooper JR, eds. Kingston, New Jersey: Civic Research Institute, Inc., pp 4-1-4-12
- 4 Barkley RA (2004), Driving impairments in teens and adults with attention-deficit/hyperactivity
5 disorder. *Psychiatr Clin North Am* 27:233-260
- 6 Barkley RA (2005), *Attention Deficit Hyperactivity Disorder: A Clinical Handbook. Third*
7 *Edition*. New York: Guilford Press
- 8 Barkley RA, Fischer M, Edelbrock CS, Smallish L (1990), The adolescent outcome of
9 hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up
10 study. *J Am Acad Child Adolesc Psychiatry* 29:546-557
- 11 Barkley RA, Fischer M, Smallish L, Fletcher K (2002), The persistence of attention-
12 deficit/hyperactivity disorder into young adulthood as a function of reporting source and
13 definition of disorder. *J Abnorm Psychol* 111:279-289
- 14 Barkley RA, Fischer M, Smallish L, Fletcher K (2004), Young adult follow-up of hyperactive
15 children: antisocial activities and drug use. *J Child Psychol Psychiatry* 45:195-211
- 16 Barkley RA, Fischer M, Smallish L, Fletcher K (2006), Young adult outcome of hyperactive
17 children: adaptive functioning in major life activities. *J Am Acad Child Adolesc*
18 *Psychiatry* 45:192-202
- 19 Biederman J (1998), Resolved: mania is mistaken for ADHD in prepubertal children,
20 affirmative. *J Am Acad Child Adolesc Psychiatry* 37:1091-1093
- 21 Biederman J (2004), Impact of comorbidity in adults with attention-deficit/hyperactivity
22 disorder. *J Clin Psychiatry* 65 Suppl 3:3-7
- 23 Biederman J, Boellner SW, Childress A, Lopez F, Krishnan S, Hodgkins P (2006), Symptoms of
24 attention-deficit/hyperactivity disorder in school-aged children with lisdexamfetamine
25 (NRP104) and mixed amphetamine salts, extended-release versus placebo. Presented at
26 the 159th Annual Meeting of the American Psychiatric Association, Toronto, Ontario,
27 Canada, May
- 28 Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marris A, Ouellette C,
29 Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J (1996), A prospective 4-year
30 follow-up study of attention-deficit hyperactivity and related disorders. *Arch Gen*
31 *Psychiatry* 53:437-446
- 32 Biederman J, Faraone SV, Keenan K, Benjamin J, Krifcher B, Moore C, Sprich-Buckminster S,
33 Ugaglia K, Jellinek MS, Steingard R (1992), Further evidence for family-genetic risk
34 factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and
35 relatives psychiatrically and pediatrically referred samples. *Arch Gen Psychiatry* 49:728-
36 738
- 37 Biederman J, Lopez FA, Boellner SW, Chandler MC (2002), A randomized, double-blind,
38 placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with
39 attention-deficit/hyperactivity disorder. *Pediatrics* 110:258-266
- 40 Biederman J, Mick E, Faraone SV (2000), Age-dependent decline of symptoms of attention
41 deficit hyperactivity disorder: impact of remission definition and symptom type. *Am J*
42 *Psychiatry* 157:816-818
- 43 Biederman J, Newcorn J, Sprich S (1991), Comorbidity of attention deficit hyperactivity disorder
44 with conduct, depressive, anxiety, and other disorders. *Am J Psychiatry* 148:564-577
- 45 Biederman J, Spencer T, Wilens T (2004), Evidence-based pharmacotherapy for attention-deficit
46 hyperactivity disorder. *Int J Neuropsychopharmacol* 7:77-97

- 1 Biederman J, Spencer TJ, Wilens TE, Prince JB, Faraone SV (2006), Commentary: Treatment of
2 ADHD with stimulant medications: Response to Nissen perspective in The New England
3 Journal of Medicine, *JAACAP* 45: 1147-1150.
- 4 Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995), Estimation of the association between
5 desipramine and the risk for sudden death in 5 to 14 year old children. *J Clin Psychiatry*
6 56:87-93
- 7 Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, Thornell A, Pfister K, Jetton
8 JG, Soriano J (1997), Is ADHD a risk factor for psychoactive substance use disorders?
9 Findings from a four-year prospective follow-up study. *J Am Acad Child Adolesc*
10 *Psychiatry* 36:21-29
- 11 Bradley C (1937), The behavior of children receiving benzedrine. *Am J Psychiatry* 94:577-585
- 12 Brown TE (2001), *The Brown Attention Deficit Disorder Scales*. San Antonio, TX:
13 Psychological Corporation
- 14 Bush G, Valera EM, Seidman LJ (2005), Functional neuroimaging of attention-
15 deficit/hyperactivity disorder: a review and suggested future directions. *Biol Psychiatry*
16 57:1273-1284
- 17 Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, Blumenthal JD,
18 James RS, Ebens CL, Walter JM, Zijdenbos A, Evans AC, Giedd JN, Rapoport JL
19 (2002), Developmental trajectories of brain volume abnormalities in children and
20 adolescents with attention-deficit/hyperactivity disorder. *JAMA* 288:1740-1748
- 21 Centers for Disease Control and Prevention (2005), Prevalence of diagnosis and medication
22 treatment for attention deficit/hyperactivity disorder-United States 2003. *MMWR*842-847
- 23 Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R (2006), Stimulant treatment over 5
24 years: effects on growth. *J Am Acad Child Adolesc Psychiatry* 45:415-421
- 25 Charach A, Ickowicz A, Schachar R (2004), Stimulant treatment over five years: adherence,
26 effectiveness, and adverse effects. *J Am Acad Child Adolesc Psychiatry* 43:559-567
- 27 Chronis AM, Chacko A, Fabiano GA, Wymbs BT, Pelham WE, Jr. (2004), Enhancements to the
28 behavioral parent training paradigm for families of children with ADHD: review and
29 future directions. *Clin Child Fam Psychol Rev* 7:1-27
- 30 Claude D, Firestone P (1995), The development of ADHD boys: a 12 year follow up. *Can J Beh*
31 *Sci* 27:226-249
- 32 Conners CK (1997), *Conners' Rating Scales-Revised*. Toronto: Multi-Health Systems, Inc.
- 33 Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M,
34 Ascher J (1996), Bupropion hydrochloride in attention deficit disorder with hyperactivity.
35 *J Am Acad Child Adolesc Psychiatry* 35:1314-1321
- 36 Conners CK, Wells K (1997), *Conners Wells Adolescent Self Report Scale*. Toronto: Multi-
37 Health Systems, Inc.
- 38 Connor DF (2002), Preschool attention deficit hyperactivity disorder: a review of prevalence,
39 diagnosis, neurobiology, and stimulant treatment. *J Dev Behav Pediatr* 23:S1-S9
- 40 Connor DF, Fletcher KE, Swanson JM (1999), A meta-analysis of clonidine for symptoms of
41 attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 38:1551-
42 1559
- 43 Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH, Jr. (2002), Psychopharmacology and
44 aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related
45 behaviors in ADHD. *J Am Acad Child Adolesc Psychiatry* 41:253-261

- 1 Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS (2004), Impact of methylphenidate
2 delivery profiles on driving performance of adolescents with attention-
3 deficit/hyperactivity disorder: a pilot study. *J Am Acad Child Adolesc Psychiatry* 43:269-
4 275
- 5 Cunningham CE, Bremner R, Secord M (1997), *COPE: the community parent education*
6 *program. A school-based family systems oriented workshop for parents of children with*
7 *disruptive behavior disorders.* Hamilton, ON, Canada: COPE Works
- 8 Daly JM, Wilens T (1998), The use of tricyclic antidepressants in children and adolescents.
9 *Pediatr Clin North Am* 45:1123-1135
- 10 Daviss WB, Scott J (2004), A chart review of cyproheptadine for stimulant-induced weight loss.
11 *J Child Adolesc Psychopharmacol* 14:65-73
- 12 DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), *ADHD Rating Scales-IV: Checklists,*
13 *Norms and Clinical Interpretation.* New York: Guilford Press
- 14 Durston S, Hulshoff Pol HE, Schnack HG, Buitelaar JK, Steenhuis MP, Minderaa RB, Kahn RS,
15 van Engeland H (2004), Magnetic resonance imaging of boys with attention-
16 deficit/hyperactivity disorder and their unaffected siblings. *J Am Acad Child Adolesc*
17 *Psychiatry* 43:332-340
- 18 Faraone SV, Biederman J (2005), What is the prevalence of adult ADHD? Results of a
19 population screen of 966 adults. *J Atten Disord* 9:384-391
- 20 Faraone SV, Biederman J, Jetton JG, Tsuang MT (1997), Attention deficit disorder and conduct
21 disorder: longitudinal evidence for a familial subtype. *Psychol Med* 27:291-300
- 22 Faraone SV, Biederman J, Monuteaux M, Spencer T (2005a), Long-term effects of extended-
23 release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on
24 growth. *J Child Adolesc Psychopharmacol* 15:191-202
- 25 Faraone SV, Biederman J, Morley CP, Spencer TJ (2006), The effect of stimulants on height and
26 weight: a review of the literature. (manuscript in preparation)
- 27 Faraone SV, Spencer TJ, Aleadri M, Pagano C, Biederman J (2003), Comparing the efficacy of
28 medications used for ADHD using meta-analysis. Presented at the 156th Annual Meeting
29 of the American Psychiatric Association, San Francisco, CA, May
- 30 Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P (2005b),
31 Molecular genetics of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 57:1313-
32 1323
- 33 Findling RL, Lopez FA (2005), Efficacy of transdermal methylphenidate with reference to
34 Concerta in ADHD. Presented at the 25th Annual Meeting of the American Academy of
35 Child and Adolescent Psychiatry, Toronto, Canada, October
- 36 Food and Drug Administration, (2005), FDA Alert [09/05]: Suicidal thinking in children and
37 adolescents. Available at: Food and Drug Administration Website
38 <http://www.fda.gov/cder/drug/infopage/atomoxetine/default.htm>. Accessed on 12-29-
39 2005.
- 40 Food and Drug Administration, (2006), Pediatric advisory committee briefing information
41 (March 22, 2006). Available at: Food and Drug Administration Website
42 <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210B-Index.htm>. Accessed on
43 4-1-2006.
- 44 Gadow KD, Sverd J (1990), Stimulants for ADHD in child patients with Tourette's syndrome:
45 the issue of relative risk. *J Dev Behav Pediatr* 11:269-71

- 1 Gadown KD, Sverd J, Sprafkin J, Nolan EE, Grossman S (1999), Long-term methylphenidate
2 therapy in children with comorbid attention-deficit hyperactivity disorder and chronic
3 multiple tic disorder [see comments]. *Arch Gen Psychiatry* 56:330-336
- 4 Gelperin,K, (2006), Psychiatric adverse events associated with drug treatment of ADHD: review
5 of post marketing safety data. Available at: Food and Drug Administration Website
6 <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210B-Index.htm>. Accessed on
7 4-1-2006.
- 8 Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, Eidevall-Wallin
9 L, Gustafsson P, Kopp S (1997), Long-term stimulant treatment of children with
10 attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-
11 controlled trial. *Arch Gen Psychiatry* 54:857-864
- 12 Gittelman-Klein R, Mannuzza S (1988), Hyperactive boys almost grown up III: methylphenidate
13 effects on ultimate height. *Arch Gen Psychiatry* 45:1131-1134
- 14 Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998), Diagnosis and treatment of attention-
15 deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs.
16 *JAMA* 279:1100-1107
- 17 Greenhill LL (2002), Stimulant medication treatment of children with attention deficit
18 hyperactivity disorder. In: *Attention Deficit Hyperactivity Disorder: State Of Science.*
19 *Best Practices*, Jensen PS, Cooper JR, eds. Kingston, NJ: Civic Research Institute, pp 9-
20 1-9-27
- 21 Greenhill LL, Ball R, Levine AJ, Muniz R, Pestreich L, Wang J (2005), Extended release
22 dexamethylphenidate in children and adolescents with ADHD. Presented at the 158th
23 Annual Meeting of the American Psychiatric Association, Atlanta, GA, May
- 24 Greenhill LL, Findling RL, Swanson JM (2002), A double-blind, placebo-controlled study of
25 modified-release methylphenidate in children with attention-deficit/hyperactivity
26 disorder. *Pediatrics* 109:E39
- 27 Greenhill LL, Kollins S, Abikoff H, McCracken JT, Riddle M, Swanson J, McGough JJ, Wigal
28 S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman JK, Cunningham C, Davies M,
29 Chuang S, Cooper T (2006a), Efficacy and safety of immediate-release methylphenidate
30 treatment for preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 45:1284-
31 1293
- 32 Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H (2006b), Efficacy and safety of
33 dexamethylphenidate extended-release capsules in children with attention-
34 deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 45:817-823
- 35 Greenhill LL, Newcorn JH, Gao H, Feldman PD (2006c), Effect of titration on adverse event
36 profile of atomoxetine. *J Am Acad Child Adolesc Psychiatry*
- 37 Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M, Wigal S, Clausen SB,
38 Zhang Y, Tulloch S (2003), A pharmacokinetic/pharmacodynamic study comparing a
39 single morning dose of adderall to twice-daily dosing in children with ADHD. *J Am Acad*
40 *Child Adolesc Psychiatry* 42:1234-1241
- 41 Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert
42 KA (1999), AHA scientific statement: cardiovascular monitoring of children and
43 adolescents receiving psychotropic drugs. *J Am Acad Child Adolesc Psychiatry* 38:1047-
44 1050

- 1 Handen BL, Feldman HM, Lurier A, Murray PJ (1999), Efficacy of methylphenidate among
2 preschool children with developmental disabilities and ADHD. *J Am Acad Child Adolesc*
3 *Psychiatry* 38:805-812
- 4 Harel EH, Brown WD (2003), Attention deficit hyperactivity disorder in elementary school
5 children in Rhode Island: associated psychosocial factors and medications used. *Clin*
6 *Pediatr (Phila)* 42:497-503
- 7 Hechtman L, Abikoff H, Klein RG, Weiss G, Respitz C, Kouri J, Blum C, Greenfield B,
8 Etcovitch J, Fleiss K, Pollack S (2004), Academic achievement and emotional status of
9 children with ADHD treated with long-term methylphenidate and multimodal
10 psychosocial treatment. *J Am Acad Child Adolesc Psychiatry* 43:812-819
- 11 Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R (1999), Treatment of attention-
12 deficit/hyperactivity disorder. *Evid Rep Technol Assess (Summ)*i-341
- 13 James SP, Mendelson WB (2004), The use of trazodone as a hypnotic: a critical review. *J Clin*
14 *Psychiatry* 65:752-755
- 15 Jensen PS (2005), Do children with ADHD get better? An MTA perspective. Presented at the
16 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry,
17 Toronto, Canada, October
- 18 Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold
19 LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham
20 WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B (2001a), ADHD
21 comorbidity findings from the MTA study: comparing comorbid subgroups. *J Am Acad*
22 *Child Adolesc Psychiatry* 40:147-158
- 23 Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB,
24 Elliott G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K,
25 Wigal T (2001b), Findings from the NIMH Multimodal Treatment Study of ADHD
26 (MTA): implications and applications for primary care providers. *J Dev Behav Pediatr*
27 22:60-73
- 28 Johnston C (2002), The impact of attention deficit hyperactivity disorder on social and
29 vocational functioning in adults. In: *Attention Deficit Hyperactivity Disorder: State of the*
30 *Science, Best Practices*, Jensen PS, Cooper JR, eds. Kingston, NJ: Civic Research
31 Institute, pp 6-2-6-21
- 32 Kessler RC, Chiu WT, Demler O, Walters EE (2005), Prevalence, severity, and comorbidity of
33 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen*
34 *Psychiatry* 62:617-627
- 35 Klein RG, Abikoff H, Hechtman L, Weiss G (2004), Design and rationale of controlled study of
36 long-term methylphenidate and multimodal psychosocial treatment in children with
37 ADHD. *J Am Acad Child Adolesc Psychiatry* 43:792-801
- 38 Klein RG, Pine DS, Klein DF (1998), Resolved: mania is mistaken for ADHD in prepubertal
39 children, negative. *J Am Acad Child Adolesc Psychiatry* 37:1093-1096
- 40 Kollins S, Greenhill L, Swanson J, Wigal S, Abikoff H, McCracken J, Riddle M, McGough J,
41 Vitiello B, Wigal T, Skrobala A, Posner K, Ghuman J, Davies M, Cunningham C, Bauzo
42 A (2006), Rationale, design, and methods of the Preschool ADHD Treatment Study
43 (PATS). *J Am Acad Child Adolesc Psychiatry* 45:1275-1283
- 44 Kovacs M, Devlin B (1998), Internalizing disorders in childhood. *J Child Psychol Psychiatry*
45 39:47-63

- 1 Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S (2000), Predictors of adult height and
2 weight in boys treated with methylphenidate for childhood behavior problems. *J Am*
3 *Acad Child Adolesc Psychiatry* 39:517-524
- 4 Kreppner JM, O'Connor TG, Rutter M (2001), Can inattention/overactivity be an institutional
5 deprivation syndrome? *J Abnorm Child Psychol* 29:513-528
- 6 Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S,
7 Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004), International
8 consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive
9 behaviour disorders (DBDs): clinical implications and treatment practice suggestions.
10 *Eur Neuropsychopharmacol* 14:11-28
- 11 Law SF, Schachar RJ (1999), Do typical clinical doses of methylphenidate cause tics in children
12 treated for attention-deficit hyperactivity disorder? *J Am Acad Child Adolesc Psychiatry*
13 38:944-951
- 14 Liberthson RR (1996), Sudden death from cardiac causes in children and young adults. *N Engl J*
15 *Med* 334:1039-1044
- 16 Lidsky TI, Schneider JS (2003), Lead neurotoxicity in children: basic mechanisms and clinical
17 correlates. *Brain* 126:5-19
- 18 Loney J, Milich M (1982), Hyperactivity, inattention, and aggression in clinical practice. In:
19 *Advances in Behavioral and Developmental Pediatrics, Vol. 3*, Wolraich M, Routh DK,
20 eds. Greenwich, CT: JAI, pp 113-147
- 21 Loo SK (2003), The EEG and ADHD. *The ADHD Report* 11:1-14
- 22 Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1993), Adult outcome of hyperactive
23 boys. Educational achievement, occupational rank, and psychiatric status. *Arch Gen*
24 *Psychiatry* 50:565-576
- 25 March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, Hechtman L, Kraemer
26 HC, Greenhill LL, Abikoff HB, Elliott LG, Jensen PS, Newcorn JH, Vitiello B, Severe J,
27 Wells KC, Pelham WE (2000), Anxiety as a predictor and outcome variable in the
28 multimodal treatment study of children with ADHD (MTA). *J Abnorm Child Psychol*
29 28:527-541
- 30 Max JE, Arndt S, Castillo CS, Bokura H, Robin DA, Lindgren SD, Smith WL Jr, Sato Y,
31 Mattheis PJ (1998), Attention-deficit hyperactivity symptomatology after traumatic brain
32 injury: a prospective study. *J Am Acad Child Adolesc Psychiatry* 37:841-847
- 33 McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, Posner K,
34 Wigal S, Pataki C, Zhang Y, Tulloch S (2003), Analog classroom assessment of a once-
35 daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. *J*
36 *Am Acad Child Adolesc Psychiatry* 42:673-683
- 37 McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M,
38 Chuang S, Wigal T, Wigal S, Posner K, Skrobala A, Kastelic E, Ghuman J, Cunningham
39 C, Shigawa S, Moyzis R, Vitiello B (2006a), Pharmacogenetics of methylphenidate
40 response in preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 45:1314-
41 1322
- 42 McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, Zhang Y, Tulloch
43 SJ (2005), Long-term tolerability and effectiveness of once-daily mixed amphetamine
44 salts (Adderall XR) in children with ADHD. *J Am Acad Child Adolesc Psychiatry*
45 44:530-538

- 1 McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E (2006b), A randomized,
2 double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate
3 transdermal system in children with ADHD. *J Atten Disord* 9:476-485
- 4 Mei Z, Grummer-Strawn LM, Thompson D, Dietz WH (2004), Shifts in percentiles of growth
5 during early childhood: analysis of longitudinal data from the California Child Health and
6 Development Study. *Pediatrics* 113:e617-e627
- 7 Michelson D (2004), Active comparator studies in the atomoxetine clinical development
8 program. Presented at the 51st Annual Meeting of the American Academy of Child and
9 Adolescent Psychiatry, San Francisco, October
- 10 Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J,
11 Dietrich A, Milton D (2003), Atomoxetine in adults with ADHD: two randomized,
12 placebo-controlled studies. *Biol Psychiatry* 53:112-120
- 13 Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal
14 RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002), Once-daily
15 atomoxetine treatment for children and adolescents with attention deficit hyperactivity
16 disorder: a randomized, placebo-controlled study. *Am J Psychiatry* 159:1896-1901
- 17 Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang
18 S, Biederman J (2004), Relapse prevention in pediatric patients with ADHD treated with
19 atomoxetine: a randomized, double-blind, placebo-controlled study. *J Am Acad Child
20 Adolesc Psychiatry* 43:896-904
- 21 Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee R, Spencer T (2001),
22 Atomoxetine in the treatment of children and adolescents with attention-
23 deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
24 *Pediatrics* 108:1-9
- 25 Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S (2002a), Case-control study of attention-
26 deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during
27 pregnancy. *J Am Acad Child Adolesc Psychiatry* 41:378-385
- 28 Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV (2002b), Impact of low birth weight on
29 attention-deficit hyperactivity disorder. *J Dev Behav Pediatr* 23:16-22
- 30 Milberger S, Biederman J, Faraone SV, Chen L, Jones J (1997), ADHD is associated with early
31 initiation of cigarette smoking in children and adolescents. *J Am Acad Child Adolesc
32 Psychiatry* 36:37-44
- 33 Mosholder, A, (2006), Psychiatric adverse events in clinical trials of drugs for attention deficit
34 hyperactivity disorder (ADHD). Available at: Food and Drug Administration Website
35 <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210B-Index.htm>. Accessed on
36 4-1-2006.
- 37 MTA Cooperative Group (1999a), 14 month randomized clinical trial of treatment strategies for
38 children with attention deficit hyperactivity disorder. *Arch Gen Psychiatry* 56:1073-1086
- 39 MTA Cooperative Group (1999b), Moderators and mediators of treatment response for children
40 with attention deficit hyperactivity disorder: the MTA study. *Arch Gen Psychiatry*
41 56:1088-1096
- 42 MTA Cooperative Group (2004a), National Institute of Mental Health Multimodal Treatment
43 Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-
44 deficit/hyperactivity disorder. *Pediatrics* 113:754-761

- 1 MTA Cooperative Group (2004b), National Institute of Mental Health Multimodal Treatment
2 Study of ADHD follow-up: changes in effectiveness and growth after the end of
3 treatment. *Pediatrics* 113:762-769
- 4 MTA Cooperative Group (2006), Effects of stimulant medication on growth rates across three
5 years in the MTA follow up. (in submission)
- 6 Muenke M (2004), Heterogeneity underlying suggestive linkage of ADHD in a genetic isolate.
7 Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent
8 Psychiatry, Washington, DC, October
- 9 Nigg JT (2006), *What Causes ADHD?* New York: Guilford
- 10 Nissen SE (2006), ADHD Drugs and Cardiovascular Risk. *N Engl J Med* 354:1445-1448
- 11 O'Malley KD, Nanson J (2002), Clinical implications of a link between fetal alcohol spectrum
12 disorder and attention-deficit hyperactivity disorder. *Can J Psychiatry* 47:349-354
- 13 Pelham WE, Burrows-MacLean L, Gnagy E, Forehand G, Fabiano G, Morrissey S, Williams A,
14 Hoffman M, Lock T, Fiebelkorn K, Morse E, Chronis A (1999), Once-a-day OROS
15 methylphenidate versus tid methylphenidate in natural settings. Presented at the 46th
16 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago,
17 October
- 18 Pelham WE, Burrows-MacLean L, Gnagy EM, Fabiano GA, Coles EK, Tresco KE, Chacko A,
19 Wymbs BT, Wienke AL, Walker KS, Hoffman MT (2005), Transdermal
20 methylphenidate, behavioral, and combined treatment for children with ADHD. *Exp Clin*
21 *Psychopharmacol* 13:111-126
- 22 Pelham WEJ, Wheeler T, Chronis A (1998), Empirically supported psychosocial treatments for
23 attention deficit hyperactivity disorder. *J Clin Child Psychol* 27:190-205
- 24 Pliszka SR (2003), Non-stimulant treatment of attention-deficit/hyperactivity disorder. *CNS*
25 *Spectr* 8:253-258
- 26 Pliszka SR, Carlson CL, Swanson JM (1999), *ADHD with Comorbid Disorders: Clinical*
27 *Assessment and Management*. New York: Guilford Press
- 28 Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT,
29 Swanson JM, Lopez M (2006a), The Texas Children's Medication Algorithm Project:
30 revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.
31 *J Am Acad Child Adolesc Psychiatry* 45:642-657
- 32 Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson CL, Conners CK, McCracken JT,
33 Swanson JM, Hughes CL, Llana ME, Lopez M, Toprac MG (2000), The Texas
34 Children's Medication Algorithm Project: report of the Texas consensus conference panel
35 on medication treatment of childhood attention deficit/hyperactivity disorder. Part I. *J Am*
36 *Acad Child Adolesc Psychiatry* 39:908-919
- 37 Pliszka SR, Matthews TL, Braslow KJ, Watson MA (2006b), Comparative effects of
38 methylphenidate and mixed salts amphetamine on height and weight in children with
39 attention-deficit/hyperactivity disorder (ADHD). *J Am Acad Child Adolesc Psychiatry*
40 45:520-526
- 41 Popper CW (1995), Combining methylphenidate and clonidine: pharmacologic questions and
42 news reports about sudden death. *J Child Adolesc Psychopharmacol* 5:157-166
- 43 Poulton A (2005), Growth on stimulant medication; clarifying the confusion: a review. *Arch Dis*
44 *Child* 90:801-806
- 45 Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T
46 (2004), Comparative pharmacodynamics and plasma concentrations of d-threo-

1 methylphenidate hydrochloride after single doses of d-threo-methylphenidate
2 hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-
3 controlled, crossover laboratory school study in children with attention-
4 deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 43:1422-1429
5 Richters JE, Arnold LE, Jensen PS, Abikoff H, Conners CK, Greenhill LL, Hechtman L,
6 Hinshaw SP, Pelham WE, Swanson JM (1995), NIMH collaborative multisite
7 multimodal treatment study of children with ADHD: I. Background and rationale. *J Am*
8 *Acad Child Adolesc Psychiatry* 34:987-1000
9 Riddle MA, Geller B, Ryan N (1993), Another sudden death in a child treated with desipramine.
10 *J Am Acad Child Adolesc Psychiatry* 32:792-797
11 Rowland AS, Umbach DM, Stallone L, Naftel AJ, Bohlig EM, Sandler DP (2002), Prevalence of
12 medication treatment for attention deficit-hyperactivity disorder among elementary
13 school children in Johnston County, North Carolina. *Am J Public Health* 92:231-234
14 Scahill L, Chappell PB, Kim YS, Schultz RT, Katsoyich L, Shepherd E, Arnsten AF, Cohen DJ,
15 Leckman JF (2001), A placebo-controlled study of guanfacine in the treatment of
16 children with tic disorders and attention deficit hyperactivity disorder. *Am J Psychiatry*
17 158:1067-1074
18 Smalley SL, Ogdie MN, McGough J, McCracken J, Loo SK, Carpenter E, Cantor R, MacPhie
19 IL, Fisher S, Monaco A, Nelson S (2004), Genome wide studies in attention deficit
20 hyperactivity disorder. Presented at the 51st Annual Meeting of the American Academy
21 of Child and Adolescent Psychiatry, Washington, DC, October
22 Smith BH, Barkley RA, Shapiro CJ (2006), Attention deficit hyperactivity disorder. In:
23 *Treatment of Childhood Disorders*, Mash EJ, Barkley RA, eds. New York: The Guilford
24 Press, pp 65-136
25 Sonuga-Barke EJ, Daley D, Thompson M (2002), Does maternal ADHD reduce the effectiveness
26 of parent training for preschool children's ADHD? *J Am Acad Child Adolesc Psychiatry*
27 41:696-702
28 Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A (2001), Parent-based
29 therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled
30 trial with a community sample. *J Am Acad Child Adolesc Psychiatry* 40:402-408
31 Sowell ER, Thompson PM, Welcome SE, Henkenius AL, Toga AW, Peterson BS (2003),
32 Cortical abnormalities in children and adolescents with attention-deficit hyperactivity
33 disorder. *Lancet* 362:1699-1707
34 Spencer T, Biederman J, Wilens T (1999), Attention-deficit/hyperactivity disorder and
35 comorbidity. *Pediatr Clin North Am* 46:915-27, vii
36 Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleari M, Herzig K,
37 Faraone S (2005), A large, double-blind, randomized clinical trial of methylphenidate in
38 the treatment of adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry*
39 57:456-463
40 Spencer TJ (2003), Oros methylphenidate treatment for ADHD: long term effect on growth.
41 Presented at the 50th Annual Meeting of the American Academy of Child and Adolescent
42 Psychiatry, Miami, October
43 Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R
44 (2006), Efficacy and safety of mixed amphetamine salts extended release (Adderall XR)
45 in the management of oppositional defiant disorder with or without comorbid attention-
46 deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week,

1 multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-
2 escalation study. *Clin Ther* 28:402-418

3 Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE (1996), Growth
4 deficits in ADHD children revisited: evidence for disorder-associated growth delays? *J*
5 *Am Acad Child Adolesc Psychiatry* 35:1460-1469

6 Sumner CS, Donnelly C, Lopez FA, Sutton V, Bakken R, Paczkowski M, Kelsey D (2005),
7 Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety.
8 Presented at the annual meeting of the American Psychiatric Association, Atlanta, GA,
9 May

10 Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G,
11 Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M,
12 Lambrecht L, Lerner M, Leventhal B, McBurnett K, Morse E, Palumbo D, Pfiffner L,
13 Stein M, Wigal S, Winans E (2000), Initiating concerta (OROS methylphenidate HCl) qd
14 in children with attention-deficit hyperactivity disorder. *J Clin Res* 3:59-76

15 Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S
16 (1999a), Acute tolerance to methylphenidate in the treatment of attention deficit
17 hyperactivity disorder in children. *Clinical Pharmacology & Therapeutics* 66:295-305

18 Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S (2003),
19 Development of a new once-a-day formulation of methylphenidate for the treatment of
20 attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
21 *Arch Gen Psychiatry* 60:204-211

22 Swanson JM (1992), *School-Based Assessments and Intervention for ADD Students*. Irvine: K.C.
23 Publishing

24 Swanson JM, Connor DF, Cantwell D (1999b), Combining methylphenidate and clonidine: ill-
25 advised. *J Am Acad Child Adolesc Psychiatry* 38:614-622

26 Swanson JM, Flockhart D, Udeh D, Cantwell D, Connor D, Williams L (1995), Clonidine in the
27 treatment of ADHD: questions about safety and efficacy. *J Child Adolesc*
28 *Psychopharmacol* 5:301-304

29 Swanson JM, Greenhill LL, Wigal T, Kollins S, Stehli-Nguyen A, Davies M, Chuang S, Vitiello
30 B, Skrobala A, Abikoff H, Oatis M, McCracken J, McGough JJ, Riddle MA, Ghuman J,
31 Cunningham C, Wigal S (2006), Stimulant-related reduction of growth rates in the
32 preschool ADHD treatment study (PATS). *J Am Acad Child Adolesc Psychiatry* 45:1304-
33 1313

34 Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S (2002a), Efficacy of a new
35 pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity
36 level in the classroom and on the playground. *J Am Acad Child Adolesc Psychiatry*
37 41:1306-1314

38 Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W,
39 Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS,
40 Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B,
41 Wells K, Wigal T, Wu M (2001), Clinical relevance of the primary findings of the MTA:
42 success rates based on severity of ADHD and ODD symptoms at the end of treatment. *J*
43 *Am Acad Child Adolesc Psychiatry* 40:168-179

44 Swanson JM, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, Freid J, Wigal S (2002b),
45 The use of a laboratory school protocol to evaluate concepts about efficacy and side
46 effects of new formulations of stimulant medications. *J Atten Disord* 6 Suppl 1:S73-S88

- 1 Swanson JM, Wigal S, Greenhill LL, Browne R, Waslick B, Lerner M, Williams L, Flynn D,
2 Agler D, Crowley K, Fineberg E, Baren M, Cantwell DP (1998a), Analog classroom
3 assessment of Adderall in children with ADHD. *J Am Acad Child Adolesc Psychiatry*
4 37:519-526
- 5 Swanson JM, Wigal SB, Udreá D, Lerner M, Agler D, Flynn D, Fineberg E, Davies M,
6 Kardatzke D, Ram A, Gupta S (1998b), Evaluation of individual subjects in the analog
7 classroom setting: I. Examples of graphical and statistical procedures for within-subject
8 ranking of responses to different delivery patterns of methylphenidate. *Psychopharmacol*
9 *Bull* 34:825-832
- 10 Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S,
11 Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ (2004), A comparison of once-
12 daily extended-release methylphenidate formulations in children with attention-
13 deficit/hyperactivity disorder in the laboratory school (the Comacs Study). *Pediatrics*
14 113:e206-e216
- 15 Swanson JM (2005), MTA 36-month outcomes: growth mixture and propensity analyses.
16 Presented at the 52nd Annual Meeting of the American Academy of Child and
17 Adolescent Psychiatry, Toronto, Canada, October
- 18 Swensen A, Michelsen D, Buesching D, Faries DE (2001), Effects of atomoxetine on social and
19 family functioning of ADHD children and adolescents. Presented at the 48th Annual
20 Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI,
21 October
- 22 Tannock R (2000), Attention deficit disorders with anxiety disorders. In: *Attention-Deficit*
23 *Disorders and Comorbidities in Children, Adolescents and Adults*, Brown TE, ed. New
24 York: American Psychiatric Press, pp 125-175
- 25 Tannock R (2002), Cognitive correlates of ADHD. In: *Attention Deficit Hyperactivity Disorder:*
26 *State of the Science. Best Practices*, Jensen PS, Cooper JR, eds. Kingston, NJ: Civic
27 Research Institute, pp 8-1-8-27
- 28 The Tourette's Syndrome Study Group (2002), Treatment of ADHD in children with tics: a
29 randomized controlled trial. *Neurology* 58:527-536
- 30 Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG (2003), Melatonin for treatment of
31 sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary
32 open label study. *Eur J Pediatr* 162:554-555
- 33 Villalaba L (2006), Follow up review of AERS search identifying cases of sudden death
34 occurring with drugs used for the treatment of attention deficit hyperactivity disorder
35 (ADHD). Available at: Food and Drug Administration Website
36 <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210B-Index.htm>. Accessed on
37 4-1-2006.
- 38 Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR,
39 Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell
40 DP (2001), Methylphenidate dosage for children with ADHD over time under controlled
41 conditions: lessons from the MTA. *J Am Acad Child Adolesc Psychiatry* 40:188-196
- 42 Weiss G, Hechtman L (2003), *Hyperactive Children Grown Up*. New York: Guilford Press
- 43 Wigal S, McGough J, Abikoff HB, Turnbow J, Posner K (2005), Behavioral effects of
44 methylphenidate transdermal system in children with ADHD. Presented at the 52nd
45 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto,
46 Canada, October

- 1 Wigal S, McGough J, McCracken JT, Clark T, Mays D, Tulloch S (2004), Analog classroom
2 study of amphetamine XR and atomoxetine for ADHD. Presented at the 51st Annual
3 Meeting of the American Academy of Child and Adolescent Psychiatry, Washington,
4 DC, October
- 5 Wigal SB, Gupta S, Guinta D, Swanson JM (1998), Reliability and validity of the SKAMP rating
6 scale in a laboratory school setting. *Psychopharmacol Bull* 34:47-53
- 7 Wigal SB, Sanchez DY, Decroy DY, D'Imperio JM, Swanson JM (2003), Selection of the
8 optimal dose ratio for a controlled-delivery formulation of methylphenidate. *Journal of*
9 *Applied Research* 3:46-63
- 10 Wigal T, Greenhill LL, Chuang S, McGough JJ, Vitiello B, Skrobala A, Swanson J, Wigal S,
11 Abikoff H, Kollins S, McCracken JT, Riddle M, Posner K, Ghuman JK, Davies M, Thorp
12 B, Stehli A (2006), Safety and tolerability of methylphenidate in preschool children with
13 ADHD. *J Am Acad Child Adolesc Psychiatry* 45:1294-1303
- 14 Wilens T, Gao H, Thomason C, Gelowitz D, Kratochvil C, Newcorn J (2004), Longer term
15 treatment with atomoxetine in adolescents with ADHD. Scientific Proceedings of the
16 American Psychiatric Association (Nr578), New York City, May
- 17 Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M (2005), ADHD treatment
18 with once daily OROS methylphenidate treatment: final results from a long term open-
19 label study. *J Am Acad Child Adolesc Psychiatry* 44:1015-1023
- 20 Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L,
21 McBurnett K, Palumbo D, Swanson J, Wolraich M (2003a), ADHD treatment with once-
22 daily OROS methylphenidate: interim 12-month results from a long-term open-label
23 study. *J Am Acad Child Adolesc Psychiatry* 42:424-433
- 24 Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T (1997), Attention deficit hyperactivity
25 disorder (ADHD) is associated with early onset substance use disorders. *J Nerv Ment Dis*
26 185:475-482
- 27 Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003b), Does stimulant therapy of
28 attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic
29 review of the literature. *Pediatrics* 111:179-185
- 30 Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners
31 CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ,
32 Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM (2006), Multisite
33 controlled study of OROS methylphenidate in the treatment of adolescents with attention-
34 deficit/hyperactivity disorder. *Arch Pediatr Adolesc Med* 160:82-90
- 35 Wilens TE, Spencer TJ (1999), Combining methylphenidate and clonidine: a clinically sound
36 medication option. *J Am Acad Child Adolesc Psychiatry* 38:614-622
- 37 Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005), Validity of the executive
38 function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. *Biol*
39 *Psychiatry* 57:1336-1346
- 40 Wolraich ML (2000), Evaluation of efficacy and safety of OROS methylphenidate HCl (MPH)
41 extended release tablets, methylphenidate tid, and placebo in children with ADHD.
42 *Pediatr Res* 47:36A
- 43 Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M,
44 McBurnett K, Bukstein O, August G (2001), Randomized, controlled trial of OROS
45 methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
46 *Pediatrics* 108:883-892

1 Wolraich ML, Lambert EW, Baumgaertel A, Garcia-Tornel S, Feurer ID, Bickman L, Doffing
2 MA (2003a), Teachers' screening for attention deficit/hyperactivity disorder: comparing
3 multinational samples on teacher ratings of ADHD. *J Abnorm Child Psychol* 31:445-455
4 Wolraich ML, Lambert W, Doffing MA, Bickman L, Simmons T, Worley K (2003b),
5 Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a
6 referred population. *J Pediatr Psychol* 28:559-567
7 Woodruff TJ, Axelrad DA, Kyle AD, Nweke O, Miller GG, Hurley BJ (2004), Trends in
8 Environmentally Related Childhood Illnesses. *Pediatrics* 113:1133-1140
9 Zametkin A, Schroth E, Faden D (2005), The role of brain imaging in the diagnosis and
10 management of ADHD. *The ADHD Report* 13:11-14
11
12



Understanding Childhood Mental Illnesses

Member Login

AACAP Quick Links

- About Us
- Child and Adolescent Psychiatrist Finder
- Facts for Families
- JobSource
- Legislative Action
- Media
- Publication Store
- Related Web Sites

Search For



AACAP Parity Legislative Alert: Parity Forums to be Held in Your State!

Representatives Patrick Kennedy (D-RI) and Jim Ramstad, (R-MN), cosponsors of the Senator Paul Wellstone Mental Health Equitable Treatment Act, have begun a six-city tour to garner support for parity legislation when it is introduced later this month.

[Click here for more](#)

Parents, Families and Educators

[Facts for Families](#) on ADHD, ODD (oppositional defiant disorder), teen suicide, psychosis, conduct disorder, bedwetting, and other topics, including the definition of a child and adolescent psychiatrist.

[ADHD - A Guide for Families](#)

To be a good advocate for your child, you need to learn as much as you can about ADHD.

[Click here for the video](#)

[Find a child and adolescent psychiatrist near you](#)

Physicians and Allied Professionals

[Meetings and Online CME](#) - information for practitioners, with focus on issues that impact patients and families, including managed care, child advocacy, violence, trauma, medical illnesses, community and social issues

[Practice Information](#)

Information surrounding access to care and the daily challenges of a changing healthcare environment

[Research](#)

Information on ongoing research initiatives and current research opportunities including research forums, the Child & Adolescent Psychiatry Clinical Trials Network, research funding opportunities, and more

AACAP Latest News

AACAP & Intermountain Academy of Child and Adolescent Psychiatry Urge Utah's Gov. Huntsman to Veto Anti-Youth Mental Health Bill

[More...](#)

What's in the News

Left Out

[More...](#)

State Legislators Pass Suicide Prevention Bill

[More...](#)

New Act by Congress Gives Boost to Autism Research

[More...](#)

Child Health Care Splits White House and States

[More...](#)

Rare No More

[More...](#)



AACAP Members

32nd Annual Review Course in Child and Adolescent Psychiatry and Training Session for the Oral Exams

[Click here for more information](#)

[Click here to register online](#)

[Maintenance of Certification](#)

[Practice Parameters](#)

[Policy Statements](#)

[CPT Codes](#)

[Systems of Care](#)

[Members Only](#)